Colon Adenocarcinoma

Cancer MONDO:0002271 Pathograph 12 Show in embeddings browser Colorectal Cancer

Colon adenocarcinoma is the most common histologic subtype of colon cancer and typically arises through the adenoma-carcinoma sequence.

Ask OpenScientist

Ask a research question about Colon Adenocarcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

9
Pathophys.
3
Histopath.
6
Phenotypes
12
Pathograph
4
Genes
6
Medical Actions
5
Datasets
26
References
2
Deep Research
⚙

Pathophysiology

9
Adenoma-Carcinoma Sequence
Stepwise progression from adenomatous polyps to invasive carcinoma drives colon adenocarcinoma development.
Show evidence (1 reference)
PMID:8055224 SUPPORT
"Molecular studies support the clinical impression that adenocarcinoma of the large intestine develops in stages. At the center of the pathological continuum between normal mucosa and invasive carcinoma is the premalignant lesion, the adenomatous polyp."
The abstract describes stage-wise progression through adenomatous polyps.
APC Loss in Intestinal Stem Cells
Wnt-pathway-activating loss of APC in intestinal stem cells drives early neoplasia.
Downstream
WNT and RAS Pathway Cooperation APC loss establishes the WNT-dysregulated background on which acquired KRAS and BRAF alterations cooperate to shape invasion and therapy response.
Show evidence (1 reference)
PMID:19092804 SUPPORT Model Organism
"Intestinal cancer is initiated by Wnt-pathway-activating mutations in genes such as adenomatous polyposis coli (APC)."
The abstract identifies APC loss and Wnt pathway activation as initiating events in intestinal cancer.
GUCY2C Tumor-Suppressive Axis Silencing
The intestinal receptor guanylyl cyclase C (GUCY2C) enforces epithelial homeostasis and restrains crypt proliferation. Early in colorectal carcinogenesis its endogenous hormones guanylin and uroguanylin are lost, silencing GUCY2C-cGMP signaling and removing a tumor-suppressive brake — a change that permits progression along the adenoma-carcinoma sequence and is the rationale for GUCY2C-agonist chemoprevention.
receptor guanylyl cyclase signaling pathway GO:0007168 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased receptor guanylyl cyclase signaling pathway (GO:0007168). GO:0007168 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Adenoma-Carcinoma Sequence Loss of GUCY2C tumor-suppressive signaling removes a brake on crypt proliferation, permitting adenoma-to-carcinoma progression.
Show evidence (1 reference)
PMID:28396341 SUPPORT Human Clinical
"Guanylate cyclase C (GUCY2C) is a tumor-suppressing receptor silenced by loss of expression of its luminocrine hormones guanylin and uroguanylin early in colorectal carcinogenesis."
Supports GUCY2C as a tumor-suppressive axis silenced early in colorectal carcinogenesis by loss of its endogenous ligands.
WNT and RAS Pathway Cooperation
Metastatic colorectal cancer typically evolves on a background of APC/WNT pathway dysregulation, with KRAS and BRAF alterations shaping invasion, therapy response, and liver metastatic fitness. These pathways reinforce proliferative signaling and resistance to anoikis during dissemination.
Wnt signaling pathway GO:0016055 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Wnt signaling pathway (GO:0016055). GO:0016055 is a biological process from the Gene Ontology. ↑ INCREASED MAPK cascade GO:0000165 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased MAPK cascade (GO:0000165). GO:0000165 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
EMT-Linked Invasive Dissemination Cooperating WNT and RAS signalling drives the invasive programs by which tumour cells detach from the primary epithelium and breach stromal barriers.
Show evidence (1 reference)
PMID:25632202 SUPPORT Human Clinical
"KRAS and BRAF mutations are associated with inferior survival, independent of MSI status, in Japanese patients with curatively resected CRC."
This supports the clinical importance of KRAS and BRAF signaling even after accounting for MSI status.
Liver Tropism and Hepatic Colonization
The liver is the dominant first metastatic site because colorectal venous drainage enters the portal circulation and because hepatic stromal, endothelial, and immune niches support tumor cell arrest and outgrowth.
cell migration GO:0016477 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell migration (GO:0016477). GO:0016477 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Seed-and-Soil Microenvironment Support Colonising tumour cells engage hepatic stromal populations, including cancer-associated fibroblasts, that create a permissive metastatic niche.
Angiogenic Remodeling Hepatic micrometastases drive angiogenic remodelling to sustain vascular adaptation and outgrowth at the secondary site.
Show evidence (1 reference)
PMID:29201802 SUPPORT Human Clinical
"The liver is the first location of metastatic disease; due to that the main mechanism of dissemination is through the portal system."
This supports the dominant hepatic tropism of metastatic colorectal cancer.
EMT-Linked Invasive Dissemination
Metastatic colorectal cancer cells detach from the primary epithelium, invade through vascular and stromal barriers, and colonize the liver through a stepwise dissemination program consistent with EMT-linked invasive plasticity.
epithelial to mesenchymal transition GO:0001837 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased epithelial to mesenchymal transition (GO:0001837). GO:0001837 is a biological process from the Gene Ontology. ↑ INCREASED positive regulation of cell migration GO:0030335 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased positive regulation of cell migration (GO:0030335). GO:0030335 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Anoikis Escape Cells that have detached from the epithelial matrix must survive that detachment to persist during portal transit.
Show evidence (1 reference)
PMID:29201802 SUPPORT Human Clinical
"Metastasis of the liver from colorectal cancer represents the final stage of a multistep biological process."
This supports a sequential detachment, invasion, and colonization program in metastatic CRC that is consistent with EMT-linked dissemination.
Anoikis Escape
A subset of metastatic colorectal cancers survives matrix detachment during transit, allowing circulating or portal-disseminating cells to persist long enough to seed the liver and other distant niches.
Downstream
Liver Tropism and Hepatic Colonization Detachment-resistant cells persist in the portal circulation long enough to arrest and colonise the liver, the dominant first metastatic site.
Show evidence (1 reference)
PMID:41027285 SUPPORT Human Clinical
"MM tumors exhibited suppressed ferroptosis and activation of the TGF-β signaling pathway, while SM tumors displayed inhibited anoikis and activation of the WNT signaling pathway, accompanied by activated angiogenesis."
This directly supports inhibition of anoikis as a distinct metastatic program in colorectal cancer liver metastasis.
Angiogenic Remodeling
Metastatic colorectal cancer promotes angiogenic remodeling at secondary sites to sustain micrometastatic survival, vascular adaptation, and outgrowth in the hepatic microenvironment.
angiogenesis GO:0001525 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased angiogenesis (GO:0001525). GO:0001525 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (1 reference)
PMID:41027285 SUPPORT Human Clinical
"MM tumors exhibited suppressed ferroptosis and activation of the TGF-β signaling pathway, while SM tumors displayed inhibited anoikis and activation of the WNT signaling pathway, accompanied by activated angiogenesis."
This directly supports activated angiogenesis as a distinct metastatic CRC program.
Seed-and-Soil Microenvironment Support
Metastatic outgrowth depends on reciprocal signaling between tumor cells and stromal populations such as cancer-associated fibroblasts, which help create a permissive hepatic microenvironment and immunosuppressive niche.
negative regulation of immune response GO:0050777 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased negative regulation of immune response (GO:0050777). GO:0050777 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (1 reference)
PMID:40530415 SUPPORT Model Organism
"Within the "seed and soil" paradigm, disrupting both tumor cells and their supportive microenvironment is essential to suppress disease progression."
This explicitly frames colorectal liver metastasis in seed-and-soil terms.
✶

Histopathology

3
High-grade tumor budding
Tumor budding - isolated single tumor cells or small clusters of up to four tumor cells at the invasive front - reflects an infiltrative, dissociative growth pattern. High-grade (BD3) budding is an established, stage-independent adverse prognostic factor now incorporated into the TNM (2017) and WHO (2019) classifications, and is associated with worse disease-free, overall, and cancer-specific survival in stage II-III colon adenocarcinoma.
Show evidence (4 references)
PMID:42322147 SUPPORT Human Clinical
"Tumour budding (TB) has been recognized as an additional prognostic factor in the TNM (2017) and WHO (2019) classification systems."
This systematic review and meta-analysis (43 studies, 17,831 patients) identifies tumor budding as a recognized, guideline-incorporated prognostic factor in colorectal cancer.
PMID:42322147 SUPPORT Human Clinical
"This study confirms that high-grade TB is an independent prognostic factor in stage II-III CRC, consistently associated with worse DFS, OS and CSS."
The pooled analysis confirms high-grade tumor budding independently predicts worse disease-free, overall, and cancer-specific survival.
PMID:28548122 SUPPORT Human Clinical
"The following 10 statements achieved consensus: tumor budding is defined as a single tumor cell or a cell cluster consisting of four tumor cells or less (22/22, 100%)."
The ITBCC consensus supplies the standardized morphologic definition used for the finding.
+ 1 more reference
Poorly differentiated clusters
Poorly differentiated clusters (PDCs) are clusters of five or more cancer cells lacking a gland-like structure. Quantifying PDCs into a site-specific grade (Grade(PDC): G1 fewer than 5, G2 5-9, G3 ten or more clusters in the field with the maximum clusters) stratifies recurrence-free survival independently of, and in the original series more strongly than, TNM stage.
Show evidence (2 references)
PMID:24418853 SUPPORT Human Clinical
"Multivariate analysis showed that Grade exerted an influence on prognostic outcome independently of TNM staging"
This 12-institution review of 3243 colorectal cancer cases shows the PDC-based grade is prognostic independently of TNM stage.
PMID:24418853 SUPPORT Human Clinical
"Grade(PDC) has a robust prognostic power and promises to be of sufficient clinical value to merit implementation as a site-specific grading system in CRC."
The authors conclude that PDC-based grading has robust, clinically implementable prognostic value.
Tumor-infiltrating lymphocytes (Immunoscore)
The type, density, and location of tumor-infiltrating lymphocytes - in particular CD3+ and cytotoxic CD8+ T cells at the tumor core and invasive margin, quantified as the consensus Immunoscore - is a favorable, stage-independent prognostic marker in colon adenocarcinoma. A dense adaptive immune infiltrate predicts lower recurrence risk and is under evaluation to help guide adjuvant chemotherapy selection.
Show evidence (2 references)
PMID:17008531 SUPPORT Human Clinical
"the immunological data (the type, density, and location of immune cells within the tumor samples) were found to be a better predictor of patient survival than the histopathological methods currently used to stage colorectal cancer."
This landmark study shows that in situ immune-cell type, density, and location predict survival better than standard histopathologic staging in colorectal cancer.
PMID:29754777 SUPPORT Human Clinical
"The Immunoscore provides a reliable estimate of the risk of recurrence in patients with colon cancer."
International validation confirms the CD3+/CD8+ tumor-infiltrating-lymphocyte-based Immunoscore reliably estimates recurrence risk in colon cancer.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Colon Adenocarcinoma Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

6
Blood 2
Anemia FREQUENT HP:0001903 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anemia (HP:0001903). HP:0001903 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35613396 SUPPORT
"We present the case of a 68-year-old female presented with a two-month history of anemia, hematochezia and abdominal pain."
Anemia is listed as a presenting feature of colon cancer.
Hematochezia FREQUENT HP:0002573 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hematochezia (HP:0002573). HP:0002573 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35613396 SUPPORT
"We present the case of a 68-year-old female presented with a two-month history of anemia, hematochezia and abdominal pain."
Hematochezia is reported as a presenting symptom.
Digestive 1
Jaundice OCCASIONAL HP:0000952 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Jaundice (HP:0000952). HP:0000952 is a phenotype from the Human Phenotype Ontology.
Constitutional 2
Abdominal Pain FREQUENT HP:0002027 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abdominal pain (HP:0002027). HP:0002027 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35613396 SUPPORT
"We present the case of a 68-year-old female presented with a two-month history of anemia, hematochezia and abdominal pain."
Abdominal pain is listed among presenting symptoms.
Fatigue VERY_FREQUENT HP:0012378 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fatigue (HP:0012378). HP:0012378 is a phenotype from the Human Phenotype Ontology.
Growth 1
Weight loss VERY_FREQUENT HP:0001824 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Weight loss (HP:0001824). HP:0001824 is a phenotype from the Human Phenotype Ontology.
🧬

Genetic Associations

4
APC (Somatic loss of function)
Gene: APC hgnc:583 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is APC (hgnc:583). hgnc:583 is a gene from the HUGO Gene Nomenclature Committee.
KRAS (Somatic activating mutation)
Gene: KRAS hgnc:6407 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is KRAS (hgnc:6407). hgnc:6407 is a gene from the HUGO Gene Nomenclature Committee.
BRAF (Somatic activating mutation)
Gene: BRAF hgnc:1097 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is BRAF (hgnc:1097). hgnc:1097 is a gene from the HUGO Gene Nomenclature Committee.
Mismatch repair deficiency / MSI-high state (Hypermutator phenotype)
💊

Medical Actions

6
Surgical Resection
Action: Definitive Surgical ResectionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Definitive Surgical Resection (NCIT:C154430). NCIT:C154430 is a clinical intervention from the NCI Thesaurus. NCIT:C154430
Surgical removal of the colon tumor when localized.
Show evidence (1 reference)
PMID:35613396 SUPPORT
"The colonoscopic study presented a tumor in the ascending colon, which after surgical resection and pathological studies, turned out to be a primary colonoc adenosquamous carcinoma."
The abstract describes surgical resection of a colon tumor.
Aspirin Chemoprevention
Action: chemopreventionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is chemoprevention, annotated with Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. Ontology label: Pharmacotherapy NCIT:C15986
Agent: aspirin CHEBI:15365 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses aspirin, annotated with acetylsalicylic acid (CHEBI:15365). CHEBI:15365 is a therapeutic agent from Chemical Entities of Biological Interest.
Low-dose aspirin is an established chemopreventive ("interception") agent that reduces the recurrence of colorectal adenomas — the precursor lesions of colon adenocarcinoma. The cited randomized trial evaluated secondary prevention in higher-risk individuals with a recent history of documented adenomas; the 81 mg dose reduced adenoma recurrence while 325 mg did not. Its antineoplastic effect in the large bowel is attributed largely to inhibition of COX/prostaglandin-driven pro-tumorigenic signaling within the adenoma-carcinoma sequence. Preventive use is balanced against gastrointestinal bleeding risk.
Mechanism Target:
INHIBITS Adenoma-Carcinoma Sequence — Aspirin reduces the incidence of colorectal adenomas and advanced neoplasia, intercepting the adenoma-to-carcinoma progression that drives colon adenocarcinoma.
Show evidence (1 reference)
PMID:12621133 SUPPORT Human Clinical
"Low-dose aspirin has a moderate chemopreventive effect on adenomas in the large bowel."
Randomized-trial evidence that low-dose aspirin reduces colorectal adenomas, supporting the INHIBITS edge on the adenoma-carcinoma sequence.
Show evidence (1 reference)
PMID:12621133 SUPPORT Human Clinical
"We performed a randomized, double-blind trial of aspirin as a chemopreventive agent against colorectal adenomas."
Establishes aspirin as a randomized-trial-tested chemopreventive agent against colorectal adenomas.
GUCY2C Agonist (Investigational Chemoprevention)
Action: chemopreventionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is chemoprevention, annotated with Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. Ontology label: Pharmacotherapy NCIT:C15986
Agent: linaclotide CHEBI:68551 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses linaclotide (CHEBI:68551). CHEBI:68551 is a therapeutic agent from Chemical Entities of Biological Interest.
Oral GUCY2C agonists (linaclotide, plecanatide) aim to reactivate the tumor-suppressive GUCY2C axis that is silenced early in colorectal carcinogenesis, restoring cGMP-dependent homeostatic signaling and restraining epithelial proliferation. In a human study oral linaclotide activated GUCY2C and reduced colorectal epithelial proliferation, but only after colon preparation — the FDA-approved gastric-release formulation does not reliably reach the colorectum, so a colorectum-targeted formulation is required before this can serve as a chemopreventive.
Mechanism Target:
RESTORES GUCY2C Tumor-Suppressive Axis Silencing — GUCY2C agonists substitute for the lost guanylin/uroguanylin ligands, reactivating GUCY2C-cGMP signaling and restoring the tumor-suppressive brake on crypt proliferation.
Show evidence (1 reference)
PMID:28396341 SUPPORT Human Clinical
"GUCY2C activation by oral linaclotide was associated with homeostatic signaling, including phosphorylation of vasodilator-stimulated phosphoprotein and inhibition of proliferation quantified by reduced Ki67-positive epithelial cells."
Demonstrates that a GUCY2C agonist reactivates homeostatic signaling and reduces epithelial proliferation, supporting the RESTORES edge.
Show evidence (1 reference)
PMID:28396341 SUPPORT Human Clinical
"The study results highlight the importance of developing a novel GUCY2C agonist formulated for release and activity targeted to the large intestine for colorectal cancer prevention"
Supports GUCY2C-agonist chemoprevention as a strategy while noting the current formulation is inadequate for the colorectum — an honest limitation.
MUC1 Peptide Vaccine (Investigational Immunoprevention)
Action: vaccinationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is vaccination (NCIT:C15346). NCIT:C15346 is a clinical intervention from the NCI Thesaurus. Ontology label: Vaccination NCIT:C15346
MUC1 is an epithelial glycoprotein aberrantly expressed on colorectal adenomas and carcinomas, making it a candidate shared antigen for immunoprevention. A MUC1 peptide vaccine aims to raise anti-MUC1 immunity to intercept recurrent adenoma formation in individuals with a prior advanced adenoma. In a randomized, placebo-controlled prevention trial the vaccine was immunogenic only in vaccine recipients but did not significantly reduce adenoma recurrence overall; a 38% absolute reduction was seen in the subset who mounted an immune response. It remains investigational.
Mechanism Target:
INHIBITS Adenoma-Carcinoma Sequence — Anti-MUC1 immunity is intended to eliminate MUC1-overexpressing adenomatous epithelium and reduce adenoma recurrence, intercepting the adenoma-carcinoma sequence; in the trial the vaccine did not reduce adenoma recurrence in the intention-to-treat population (aRR 0.83, 95% CI 0.60-1.14, P = 0.25), and the 38% absolute reduction observed in immune responders was likewise not statistically significant (aRR 0.41, 95% CI 0.15-1.11, P = 0.08) — hypothesis-generating rather than confirmatory.
Show evidence (1 reference)
PMID:36892581 SUPPORT Human Clinical
"a 38% absolute reduction in adenoma recurrence compared with placebo was observed in participants who had an immune response at week 12 and with the booster injection."
Randomized-trial evidence of a hypothesis-generating signal — a 38% absolute reduction in adenoma recurrence was observed only in immune responders and was not statistically significant (P = 0.08), with no effect in the intention-to-treat population (P = 0.25) — supporting a qualified, non-confirmatory INHIBITS edge on the adenoma-carcinoma sequence.
Show evidence (1 reference)
PMID:36892581 SUPPORT Human Clinical
"An immune response was observed only in vaccine recipients."
Confirms the MUC1 peptide vaccine is immunogenic in the colorectal adenoma prevention setting.
Encorafenib Plus Binimetinib and Cetuximab for BRAF V600E Disease
Action: targeted therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is targeted therapy (NCIT:C93352). NCIT:C93352 is a clinical intervention from the NCI Thesaurus. Ontology label: Targeted Therapy NCIT:C93352
Agent: encorafenib NCIT:C98283 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses encorafenib (NCIT:C98283). NCIT:C98283 is a therapeutic agent from the NCI Thesaurus. binimetinib CHEBI:145371 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses binimetinib (CHEBI:145371). CHEBI:145371 is a therapeutic agent from Chemical Entities of Biological Interest. cetuximab NCIT:C1723 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses cetuximab (NCIT:C1723). NCIT:C1723 is a therapeutic agent from the NCI Thesaurus.
Encorafenib, binimetinib, and cetuximab provide a targeted regimen for BRAF V600E-mutant metastatic colorectal cancer, pairing BRAF and MEK inhibition with EGFR blockade to suppress MAPK feedback signaling.
Show evidence (1 reference)
DOI:10.1200/jco.22.01693 SUPPORT Human Clinical
"The positive BEACON colorectal cancer (CRC) safety lead-in, evaluating encorafenib + cetuximab + binimetinib in previously treated patients with BRAFV600E-mutated metastatic CRC (mCRC), prompted the design of the phase II ANCHOR CRC study (ClinicalTrails.gov identifier: NCT03693170 )."
The phase II ANCHOR CRC study directly evaluates this BRAF/MEK/EGFR targeted combination in BRAF V600E-mutant metastatic CRC.
Cetuximab for RAS Wild-Type Disease Stratified by APC Mutation Status
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: cetuximab NCIT:C1723 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses cetuximab (NCIT:C1723). NCIT:C1723 is a therapeutic agent from the NCI Thesaurus.
Cetuximab combined with chemotherapy for RAS wild-type metastatic CRC shows improved outcomes in APC-mutant tumors. APC mutation status serves as a predictive biomarker, with APC-mutant tumors achieving higher response rates and longer overall survival compared to APC wild-type tumors, suggesting that Wnt pathway dysregulation influences EGFR inhibitor sensitivity.
Show evidence (2 references)
PMID:42199488 SUPPORT Human Clinical
"partial response was achieved in 64 patients with APC-mutated tumors (85%) and 17 patients with APC wild type tumors (59%). There was a significant difference in the objective response rate (ORR) between patients with APC mutation and wild type (p-value of 0.003)."
This clinical study demonstrates APC mutation status as a predictive biomarker for cetuximab response in RAS wild-type disease, with significantly higher objective response rates in APC-mutant patients.
PMID:42199488 SUPPORT Human Clinical
"The median OS was not reached (95% CI, 31.5-NA) in patients with the APC mutation, whereas it was 37.3 months (95% CI, 23.4-NA) in those with APC-wild type tumors (p = 0.024)."
APC-mutant patients treated with cetuximab-containing chemotherapy show significantly longer median overall survival compared to APC wild-type patients.
🌍

Environmental Factors

2
Obesity
Obesity increases colorectal cancer risk and can reinforce inflammatory programs linked to metastatic progression.
Show evidence (1 reference)
PMID:18086756 SUPPORT Human Clinical
"the estimated relative risk of colorectal cancer was 1.19 [95% confidence interval (95% CI), 1.11-1.29], comparing obese (BMI > or = 30 kg/m(2)) with normal weight (BMI <25 kg/m(2)) people"
Meta-analysis of 31 studies quantifies obesity's association with colorectal cancer risk.
Alcohol exposure
exposure to alcohol consumption ECTO:0001082 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to alcohol consumption (ECTO:0001082). ECTO:0001082 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Alcohol contributes to colorectal cancer risk and often coexists with metabolic and inflammatory exposures.
Show evidence (1 reference)
PMID:21307158 SUPPORT Human Clinical
"The RRs were 1.21 [95% confidence interval (CI) 1.13-1.28] for moderate and 1.52 (95% CI 1.27-1.81) for heavy (≥4 drinks/day) alcohol drinking"
Dose-response meta-analysis quantifies alcohol's association with colorectal cancer risk.
🪜

Stages

2
Localized
Disease confined to the bowel wall and regional nodes, where resection with or without adjuvant chemotherapy is potentially curative.
Metastatic
Advanced colorectal adenocarcinoma with distant spread, most commonly hepatic. Liver colonization, KRAS/BRAF-driven signaling, WNT pathway activation, and stromal cooperation are recurring mechanistic themes; MSI-high disease represents a distinct immune-responsive metastatic subset.
Folded in from the former Metastatic_Colorectal_Cancer entry (cancer granularity ladder, design decisions §3a). That entry was scoped to colorectal cancer broadly (MONDO:0005575); its dissemination biology is carried by this entry's Liver Tropism and Hepatic Colonization, EMT-Linked Invasive Dissemination, Anoikis Escape, Angiogenic Remodeling, and Seed-and-Soil Microenvironment Support nodes.
Show evidence (2 references)
PMID:33591350 SUPPORT Human Clinical
"Of new colorectal cancer diagnoses, 20% of patients have metastatic disease at presentation and another 25% who present with localized disease will later develop metastases."
Quantifies presentation frequency of the metastatic stage.
PMID:33591350 SUPPORT Human Clinical
"Among people diagnosed with metastatic colorectal cancer, approximately 70% to 75% of patients survive beyond 1 year, 30% to 35% beyond 3 years, and fewer than 20% beyond 5 years from diagnosis."
Provides survival benchmarks for the metastatic stage.
📊

Related Datasets

5
Gene expression Classification of Colon Cancer defines six molecular subtypes with distinct clinical, molecular and survival characteristics [Expression] geo:GSE39582
Microarray dataset with colorectal cancer and non-tumoral mucosa samples used for molecular classification and outcome studies.
human MICROARRAY n=462
colon tissue UBERON:0001155 Uberon multi-species anatomy ontology (UBERON) Relation: this dataset samples this sample type This dataset samples colon tissue, annotated with colon (UBERON:0001155). UBERON:0001155 is a sample type from the Uberon multi-species anatomy ontology.
Conditions: colorectal cancer non-tumoral colonic mucosa
Includes 443 colorectal cancer samples and 19 non-tumoral mucosa samples.
Multi-region sequencing of metastatic colorectal cancer ega:EGAS00001002539
In order to reconstruct the evolutionary history of metastatic colorectal cancer, we performed whole-exome sequencing of 10 metastatic colorectal cancer patients for whom the primary tumor and matched distant metastases to the brain (n=10), liver (n=1), lung (n=1), as well as lymph node metastases (n=4) were available. For 6 of the 10 patients, multiple regions (n=2-5) of the primary tumor and distant metastases were sequenced.
human
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Metastatic Colorectal Cancer"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Multi-region sequencing of metastatic colorectal cancer ega:EGAS00001003568
human WES
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Metastatic Colorectal Cancer"); description-level mentions were not accepted. EGA study_type: Exome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Multi-Region WES of Metastatic Colorectal Cancer ega:EGAS00001003573
human
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Metastatic Colorectal Cancer"); description-level mentions were not accepted. EGA study_type: Cancer Genomics. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Comparative Analysis of Primary and Metastatic Colorectal Cancer dbgap:phs000790
Molecular profiling for somatic mutations that predict response to anti-EGFR therapy in colorectal cancer (CRC) has become standard practice. However, abundant tissue from metastatic lesions is not always available from patients with metastatic CRC. Concerns involving genetic heterogeneity between primary and metastatic lesions have called into question the suitability of profiling primary tumors in patients with metastatic disease.
Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Metastatic Colorectal Cancer"). Retrieved 2026-08-02.
{ }

Source YAML

click to show 
name: Colon Adenocarcinoma
creation_date: '2026-02-02T00:16:36Z'
category: Cancer
parents:
- Colorectal Cancer
disease_term:
  preferred_term: colon adenocarcinoma
  term:
    id: MONDO:0002271
    label: colon adenocarcinoma
gene_sets:
- gene_set: MYGENESET:KEGG_COLORECTAL_CANCER
  relationship: CANONICAL_PATHWAY
  note: >-
    KEGG colorectal cancer pathway (Wnt/APC, proliferation, MAPK). Precise link:
    this base adenocarcinoma entry, not the metastatic entry — EMT/invasion BPs
    are carried by this entry's Metastatic-stage nodes (the former Metastatic_Colorectal_Cancer entry was folded in).
description: >-
  Colon adenocarcinoma is the most common histologic subtype of colon cancer and
  typically arises through the adenoma-carcinoma sequence.
stages:
- name: Localized
  description: >-
    Disease confined to the bowel wall and regional nodes, where resection
    with or without adjuvant chemotherapy is potentially curative.
- name: Metastatic
  description: >-
    Advanced colorectal adenocarcinoma with distant spread, most commonly
    hepatic. Liver colonization, KRAS/BRAF-driven signaling, WNT pathway
    activation, and stromal cooperation are recurring mechanistic themes;
    MSI-high disease represents a distinct immune-responsive metastatic
    subset.
  notes: >-
    Folded in from the former Metastatic_Colorectal_Cancer entry (cancer
    granularity ladder, design decisions §3a). That entry was scoped to
    colorectal cancer broadly (MONDO:0005575); its dissemination biology is
    carried by this entry's Liver Tropism and Hepatic Colonization,
    EMT-Linked Invasive Dissemination, Anoikis Escape, Angiogenic Remodeling,
    and Seed-and-Soil Microenvironment Support nodes.
  evidence:
  - reference: PMID:33591350
    reference_title: "Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Of new colorectal cancer diagnoses, 20% of patients have metastatic disease at presentation and another 25% who present with localized disease will later develop metastases.
    explanation: Quantifies presentation frequency of the metastatic stage.
  - reference: PMID:33591350
    reference_title: "Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among people diagnosed with metastatic colorectal cancer, approximately 70% to 75% of patients survive beyond 1 year, 30% to 35% beyond 3 years, and fewer than 20% beyond 5 years from diagnosis.
    explanation: Provides survival benchmarks for the metastatic stage.
pathophysiology:
- name: Adenoma-Carcinoma Sequence
  description: >-
    Stepwise progression from adenomatous polyps to invasive carcinoma drives
    colon adenocarcinoma development.
  evidence:
  - reference: PMID:8055224
    reference_title: "The adenoma carcinoma sequence in colorectal neoplasia."
    supports: SUPPORT
    snippet: "Molecular studies support the clinical impression that adenocarcinoma
      of the large intestine develops in stages. At the center of the pathological
      continuum between normal mucosa and invasive carcinoma is the premalignant lesion,
      the adenomatous polyp."
    explanation: The abstract describes stage-wise progression through
      adenomatous polyps.
- name: APC Loss in Intestinal Stem Cells
  description: >-
    Wnt-pathway-activating loss of APC in intestinal stem cells drives early
    neoplasia.
  evidence:
  - reference: PMID:19092804
    reference_title: "Crypt stem cells as the cells-of-origin of intestinal cancer."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Intestinal cancer is initiated by Wnt-pathway-activating mutations in
      genes such as adenomatous polyposis coli (APC)."
    explanation: The abstract identifies APC loss and Wnt pathway activation as
      initiating events in intestinal cancer.
  downstream:
  - target: WNT and RAS Pathway Cooperation
    description: >-
      APC loss establishes the WNT-dysregulated background on which acquired KRAS
      and BRAF alterations cooperate to shape invasion and therapy response.
- name: GUCY2C Tumor-Suppressive Axis Silencing
  biological_scale: MOLECULAR
  description: >-
    The intestinal receptor guanylyl cyclase C (GUCY2C) enforces epithelial
    homeostasis and restrains crypt proliferation. Early in colorectal
    carcinogenesis its endogenous hormones guanylin and uroguanylin are lost,
    silencing GUCY2C-cGMP signaling and removing a tumor-suppressive brake — a
    change that permits progression along the adenoma-carcinoma sequence and is
    the rationale for GUCY2C-agonist chemoprevention.
  biological_processes:
  - preferred_term: receptor guanylyl cyclase signaling pathway
    modifier: DECREASED
    term:
      id: GO:0007168
      label: receptor guanylyl cyclase signaling pathway
  downstream:
  - target: Adenoma-Carcinoma Sequence
    description: >-
      Loss of GUCY2C tumor-suppressive signaling removes a brake on crypt
      proliferation, permitting adenoma-to-carcinoma progression.
  evidence:
  - reference: PMID:28396341
    reference_title: "Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Guanylate cyclase C (GUCY2C) is a tumor-suppressing receptor silenced by loss of expression of its luminocrine hormones guanylin and uroguanylin early in colorectal carcinogenesis."
    explanation: Supports GUCY2C as a tumor-suppressive axis silenced early in
      colorectal carcinogenesis by loss of its endogenous ligands.
- name: WNT and RAS Pathway Cooperation
  description: >-
    Metastatic colorectal cancer typically evolves on a background of APC/WNT pathway
    dysregulation, with KRAS and BRAF alterations shaping invasion, therapy response,
    and
    liver metastatic fitness. These pathways reinforce proliferative signaling and
    resistance to anoikis during dissemination.
  evidence:
  - reference: PMID:25632202
    reference_title: Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: KRAS and BRAF mutations are associated with inferior survival, independent of MSI status, in Japanese patients with curatively resected CRC.
    explanation: This supports the clinical importance of KRAS and BRAF signaling even after accounting for MSI status.
  biological_processes:
  - preferred_term: Wnt signaling pathway
    modifier: INCREASED
    term:
      id: GO:0016055
      label: Wnt signaling pathway
  - preferred_term: MAPK cascade
    modifier: INCREASED
    term:
      id: GO:0000165
      label: MAPK cascade
  downstream:
  - target: EMT-Linked Invasive Dissemination
    description: >-
      Cooperating WNT and RAS signalling drives the invasive programs by which
      tumour cells detach from the primary epithelium and breach stromal barriers.
- name: Liver Tropism and Hepatic Colonization
  conforms_to: "invasion_and_metastasis#Circulatory Survival and Extravasation"
  description: >-
    The liver is the dominant first metastatic site because colorectal venous drainage
    enters the portal circulation and because hepatic stromal, endothelial, and immune
    niches support tumor cell arrest and outgrowth.
  evidence:
  - reference: PMID:29201802
    reference_title: Hepatic Metastasis from Colorectal Cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The liver is the first location of metastatic disease; due to that the main mechanism of dissemination is through the portal system.
    explanation: This supports the dominant hepatic tropism of metastatic colorectal cancer.
  biological_processes:
  - preferred_term: cell migration
    modifier: INCREASED
    term:
      id: GO:0016477
      label: cell migration
  downstream:
  - target: Seed-and-Soil Microenvironment Support
    description: >-
      Colonising tumour cells engage hepatic stromal populations, including
      cancer-associated fibroblasts, that create a permissive metastatic niche.
  - target: Angiogenic Remodeling
    description: >-
      Hepatic micrometastases drive angiogenic remodelling to sustain vascular
      adaptation and outgrowth at the secondary site.
- name: EMT-Linked Invasive Dissemination
  conforms_to: "invasion_and_metastasis#Epithelial-Mesenchymal Transition Activation"
  description: >-
    Metastatic colorectal cancer cells detach from the primary epithelium, invade
    through vascular and stromal barriers, and colonize the liver through a stepwise
    dissemination program consistent with EMT-linked invasive plasticity.
  evidence:
  - reference: PMID:29201802
    reference_title: Hepatic Metastasis from Colorectal Cancer.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Metastasis of the liver from colorectal cancer represents the final stage of a multistep biological process.
    explanation: This supports a sequential detachment, invasion, and colonization program in metastatic CRC that is consistent with EMT-linked dissemination.
  biological_processes:
  - preferred_term: epithelial to mesenchymal transition
    modifier: INCREASED
    term:
      id: GO:0001837
      label: epithelial to mesenchymal transition
  - preferred_term: positive regulation of cell migration
    modifier: INCREASED
    term:
      id: GO:0030335
      label: positive regulation of cell migration
  downstream:
  - target: Anoikis Escape
    description: >-
      Cells that have detached from the epithelial matrix must survive that
      detachment to persist during portal transit.
- name: Anoikis Escape
  description: >-
    A subset of metastatic colorectal cancers survives matrix detachment during transit,
    allowing circulating or portal-disseminating cells to persist long enough to seed
    the liver and other distant niches.
  evidence:
  - reference: PMID:41027285
    reference_title: Proteomic landscape of colorectal cancer liver metastasis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: MM tumors exhibited suppressed ferroptosis and activation of the TGF-β signaling pathway, while SM tumors displayed inhibited anoikis and activation of the WNT signaling pathway, accompanied by activated angiogenesis.
    explanation: This directly supports inhibition of anoikis as a distinct metastatic program in colorectal cancer liver metastasis.
  downstream:
  - target: Liver Tropism and Hepatic Colonization
    description: >-
      Detachment-resistant cells persist in the portal circulation long enough to
      arrest and colonise the liver, the dominant first metastatic site.
- name: Angiogenic Remodeling
  description: >-
    Metastatic colorectal cancer promotes angiogenic remodeling at secondary sites
    to
    sustain micrometastatic survival, vascular adaptation, and outgrowth in the hepatic
    microenvironment.
  evidence:
  - reference: PMID:41027285
    reference_title: Proteomic landscape of colorectal cancer liver metastasis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: MM tumors exhibited suppressed ferroptosis and activation of the TGF-β signaling pathway, while SM tumors displayed inhibited anoikis and activation of the WNT signaling pathway, accompanied by activated angiogenesis.
    explanation: This directly supports activated angiogenesis as a distinct metastatic CRC program.
  biological_processes:
  - preferred_term: angiogenesis
    modifier: INCREASED
    term:
      id: GO:0001525
      label: angiogenesis
- name: Seed-and-Soil Microenvironment Support
  description: >-
    Metastatic outgrowth depends on reciprocal signaling between tumor cells and stromal
    populations such as cancer-associated fibroblasts, which help create a permissive
    hepatic microenvironment and immunosuppressive niche.
  evidence:
  - reference: PMID:40530415
    reference_title: A dual-targeting strategy to inhibit colorectal cancer liver metastasis via tumor cell ferroptosis and cancer-associated fibroblast reprogramming.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Within the "seed and soil" paradigm, disrupting both tumor cells and their supportive microenvironment is essential to suppress disease progression.
    explanation: This explicitly frames colorectal liver metastasis in seed-and-soil terms.
  biological_processes:
  - preferred_term: negative regulation of immune response
    modifier: INCREASED
    term:
      id: GO:0050777
      label: negative regulation of immune response
phenotypes:
- name: Anemia
  category: Hematologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: PMID:35613396
    reference_title: "[Adenosquamous carcinoma of the colon: a case report and review of the literature]."
    supports: SUPPORT
    snippet: "We present the case of a 68-year-old female presented with a two-month
      history of anemia, hematochezia and abdominal pain."
    explanation: Anemia is listed as a presenting feature of colon cancer.
- name: Hematochezia
  category: Gastrointestinal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hematochezia
    term:
      id: HP:0002573
      label: Hematochezia
  evidence:
  - reference: PMID:35613396
    reference_title: "[Adenosquamous carcinoma of the colon: a case report and review of the literature]."
    supports: SUPPORT
    snippet: "We present the case of a 68-year-old female presented with a two-month
      history of anemia, hematochezia and abdominal pain."
    explanation: Hematochezia is reported as a presenting symptom.
- name: Abdominal Pain
  category: Gastrointestinal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:35613396
    reference_title: "[Adenosquamous carcinoma of the colon: a case report and review of the literature]."
    supports: SUPPORT
    snippet: "We present the case of a 68-year-old female presented with a two-month
      history of anemia, hematochezia and abdominal pain."
    explanation: Abdominal pain is listed among presenting symptoms.
- category: Constitutional
  name: Weight loss
  frequency: VERY_FREQUENT
  description: Metastatic colorectal cancer commonly causes catabolic weight loss.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Constitutional
  name: Fatigue
  frequency: VERY_FREQUENT
  description: Fatigue arises from chronic inflammation, anemia, treatment toxicity, and extensive disease.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Hepatic
  name: Jaundice
  frequency: OCCASIONAL
  description: Jaundice may appear with bulky liver metastases or biliary obstruction.
  phenotype_term:
    preferred_term: Jaundice
    term:
      id: HP:0000952
      label: Jaundice
histopathology:
- name: High-grade tumor budding
  finding_term:
    preferred_term: Tumor budding
    term:
      id: HP:0025461
      label: Abnormal cell morphology
  description: >-
    Tumor budding - isolated single tumor cells or small clusters of up to four
    tumor cells at the invasive front - reflects an infiltrative, dissociative
    growth pattern. High-grade (BD3) budding is an established,
    stage-independent adverse prognostic factor now incorporated into the TNM
    (2017) and WHO (2019) classifications, and is associated with worse
    disease-free, overall, and cancer-specific survival in stage II-III colon
    adenocarcinoma.
  notes: >-
    finding_term falls back to HP:0025461 because NCIT has no tumor-budding term
    in the Histopathology Result branch (searched 2026-08-17). The fallback is
    defensible here - budding is genuinely a cell-arrangement/morphology finding -
    but a targeted NCIT term request would be the better long-term fix.
  evidence:
  - reference: PMID:42322147
    reference_title: "The prognostic value of tumour budding for survival in stage II and III colorectal cancer: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tumour budding (TB) has been recognized as an additional prognostic
      factor in the TNM (2017) and WHO (2019) classification systems."
    explanation: >-
      This systematic review and meta-analysis (43 studies, 17,831 patients)
      identifies tumor budding as a recognized, guideline-incorporated prognostic
      factor in colorectal cancer.
  - reference: PMID:42322147
    reference_title: "The prognostic value of tumour budding for survival in stage II and III colorectal cancer: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study confirms that high-grade TB is an independent prognostic
      factor in stage II-III CRC, consistently associated with worse DFS, OS and CSS."
    explanation: >-
      The pooled analysis confirms high-grade tumor budding independently predicts
      worse disease-free, overall, and cancer-specific survival.
  - reference: PMID:28548122
    reference_title: "Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The following 10 statements achieved consensus: tumor budding is defined as a single tumor cell or a cell cluster consisting of four tumor cells or less (22/22, 100%)."
    explanation: >-
      The ITBCC consensus supplies the standardized morphologic definition used
      for the finding.
  - reference: PMID:28548122
    reference_title: "Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tumor budding is an independent predictor of lymph node metastases in pT1 colorectal cancer (23/23, 100%)."
    explanation: >-
      The international consensus establishes the independent prognostic value
      of tumor budding for lymph-node metastasis in early colorectal cancer.
- name: Poorly differentiated clusters
  finding_term:
    preferred_term: Poorly differentiated clusters
    term:
      id: HP:0025461
      label: Abnormal cell morphology
  description: >-
    Poorly differentiated clusters (PDCs) are clusters of five or more cancer
    cells lacking a gland-like structure. Quantifying PDCs into a site-specific
    grade (Grade(PDC): G1 fewer than 5, G2 5-9, G3 ten or more clusters in the
    field with the maximum clusters) stratifies recurrence-free survival
    independently of, and in the original series more strongly than, TNM stage.
  notes: >-
    finding_term falls back to HP:0025461 because NCIT has no poorly-differentiated-cluster
    or Grade(PDC) term in the Histopathology Result branch (searched 2026-08-17);
    its retired "Poorly Differentiated" grade term is a tumor-differentiation grade,
    not this cluster-counting finding. PDCs are a genuine cell-arrangement and
    differentiation finding, so the fallback fits better here than for the TIL finding.
  evidence:
  - reference: PMID:24418853
    reference_title: "Site-specific tumor grading system in colorectal cancer: multicenter pathologic review of the value of quantifying poorly differentiated clusters."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Multivariate analysis showed that Grade exerted an influence on
      prognostic outcome independently of TNM staging"
    explanation: >-
      This 12-institution review of 3243 colorectal cancer cases shows the PDC-based
      grade is prognostic independently of TNM stage.
  - reference: PMID:24418853
    reference_title: "Site-specific tumor grading system in colorectal cancer: multicenter pathologic review of the value of quantifying poorly differentiated clusters."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Grade(PDC) has a robust prognostic power and promises to be of
      sufficient clinical value to merit implementation as a site-specific grading
      system in CRC."
    explanation: >-
      The authors conclude that PDC-based grading has robust, clinically
      implementable prognostic value.
- name: Tumor-infiltrating lymphocytes (Immunoscore)
  finding_term:
    preferred_term: Tumor-infiltrating lymphocytes
    term:
      id: NCIT:C35983
      label: Lymphocytic Infiltrate
  description: >-
    The type, density, and location of tumor-infiltrating lymphocytes - in
    particular CD3+ and cytotoxic CD8+ T cells at the tumor core and invasive
    margin, quantified as the consensus Immunoscore - is a favorable,
    stage-independent prognostic marker in colon adenocarcinoma. A dense adaptive
    immune infiltrate predicts lower recurrence risk and is under evaluation to
    help guide adjuvant chemotherapy selection.
  notes: >-
    finding_term is NCIT:C35983 Lymphocytic Infiltrate, "a morphologic finding
    referring to the presence of a cellular infiltrate that is composed of
    non-neoplastic or neoplastic lymphocytes in a tissue sample" - the closest
    match to the Immunoscore reading, which is a CD3+/CD8+ lymphocyte density.
    Candidates passed over (searched 2026-08-17, revised 2026-08-25):
    NCIT:C35980 Chronic Inflammatory Infiltrate is a morphologic finding but
    asserts a chronic-inflammatory character and admits lymphoplasmacytic cells
    and reactive plasma cells that the Immunoscore does not measure;
    NCIT:C12546 Tumor Infiltrating Lymphocyte is a cell type rather than a
    finding; NCIT:C160833 Tumor Infiltrating Lymphocyte Absent asserts the
    inverse of this finding; NCIT:C160832 and NCIT:C204678 are a CRF question
    and a count measurement rather than findings. The specific CD3+/CD8+
    Immunoscore reading is carried by preferred_term and the description.
  evidence:
  - reference: PMID:17008531
    reference_title: "Type, density, and location of immune cells within human colorectal tumors predict clinical outcome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the immunological data (the type, density, and location of immune
      cells within the tumor samples) were found to be a better predictor of patient
      survival than the histopathological methods currently used to stage colorectal
      cancer."
    explanation: >-
      This landmark study shows that in situ immune-cell type, density, and location
      predict survival better than standard histopathologic staging in colorectal cancer.
  - reference: PMID:29754777
    reference_title: "International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Immunoscore provides a reliable estimate of the risk of recurrence
      in patients with colon cancer."
    explanation: >-
      International validation confirms the CD3+/CD8+ tumor-infiltrating-lymphocyte-based
      Immunoscore reliably estimates recurrence risk in colon cancer.
treatments:
- name: Surgical Resection
  description: Surgical removal of the colon tumor when localized.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Definitive Surgical Resection
    term:
      id: NCIT:C154430
      label: Definitive Surgical Resection
  evidence:
  - reference: PMID:35613396
    reference_title: "[Adenosquamous carcinoma of the colon: a case report and review of the literature]."
    supports: SUPPORT
    snippet: "The colonoscopic study presented a tumor in the ascending colon, which
      after surgical resection and pathological studies, turned out to be a primary
      colonoc adenosquamous carcinoma."
    explanation: The abstract describes surgical resection of a colon tumor.
- name: Aspirin Chemoprevention
  description: >-
    Low-dose aspirin is an established chemopreventive ("interception") agent that
    reduces the recurrence of colorectal adenomas — the precursor lesions of colon
    adenocarcinoma. The cited randomized trial evaluated secondary prevention in
    higher-risk individuals with a recent history of documented adenomas; the
    81 mg dose reduced adenoma recurrence while 325 mg did not. Its antineoplastic
    effect in the large bowel is attributed largely to inhibition of
    COX/prostaglandin-driven pro-tumorigenic signaling within the adenoma-carcinoma
    sequence. Preventive use is balanced against gastrointestinal bleeding risk.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: chemoprevention
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: aspirin
      term:
        id: CHEBI:15365
        label: acetylsalicylic acid
  target_mechanisms:
  - target: Adenoma-Carcinoma Sequence
    treatment_effect: INHIBITS
    description: >-
      Aspirin reduces the incidence of colorectal adenomas and advanced neoplasia,
      intercepting the adenoma-to-carcinoma progression that drives colon
      adenocarcinoma.
    evidence:
    - reference: PMID:12621133
      reference_title: "A randomized trial of aspirin to prevent colorectal adenomas."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Low-dose aspirin has a moderate chemopreventive effect on adenomas in the large bowel."
      explanation: Randomized-trial evidence that low-dose aspirin reduces
        colorectal adenomas, supporting the INHIBITS edge on the adenoma-carcinoma
        sequence.
  evidence:
  - reference: PMID:12621133
    reference_title: "A randomized trial of aspirin to prevent colorectal adenomas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We performed a randomized, double-blind trial of aspirin as a chemopreventive agent against colorectal adenomas."
    explanation: Establishes aspirin as a randomized-trial-tested chemopreventive
      agent against colorectal adenomas.
- name: GUCY2C Agonist (Investigational Chemoprevention)
  description: >-
    Oral GUCY2C agonists (linaclotide, plecanatide) aim to reactivate the
    tumor-suppressive GUCY2C axis that is silenced early in colorectal
    carcinogenesis, restoring cGMP-dependent homeostatic signaling and restraining
    epithelial proliferation. In a human study oral linaclotide activated GUCY2C
    and reduced colorectal epithelial proliferation, but only after colon
    preparation — the FDA-approved gastric-release formulation does not reliably
    reach the colorectum, so a colorectum-targeted formulation is required before
    this can serve as a chemopreventive.
  therapeutic_modality: PEPTIDE
  treatment_term:
    preferred_term: chemoprevention
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: linaclotide
      term:
        id: CHEBI:68551
        label: linaclotide
  target_mechanisms:
  - target: GUCY2C Tumor-Suppressive Axis Silencing
    treatment_effect: RESTORES
    description: >-
      GUCY2C agonists substitute for the lost guanylin/uroguanylin ligands,
      reactivating GUCY2C-cGMP signaling and restoring the tumor-suppressive brake
      on crypt proliferation.
    evidence:
    - reference: PMID:28396341
      reference_title: "Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "GUCY2C activation by oral linaclotide was associated with homeostatic signaling, including phosphorylation of vasodilator-stimulated phosphoprotein and inhibition of proliferation quantified by reduced Ki67-positive epithelial cells."
      explanation: Demonstrates that a GUCY2C agonist reactivates homeostatic
        signaling and reduces epithelial proliferation, supporting the RESTORES edge.
  evidence:
  - reference: PMID:28396341
    reference_title: "Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The study results highlight the importance of developing a novel GUCY2C agonist formulated for release and activity targeted to the large intestine for colorectal cancer prevention"
    explanation: Supports GUCY2C-agonist chemoprevention as a strategy while noting
      the current formulation is inadequate for the colorectum — an honest limitation.
- name: MUC1 Peptide Vaccine (Investigational Immunoprevention)
  description: >-
    MUC1 is an epithelial glycoprotein aberrantly expressed on colorectal adenomas
    and carcinomas, making it a candidate shared antigen for immunoprevention. A
    MUC1 peptide vaccine aims to raise anti-MUC1 immunity to intercept recurrent
    adenoma formation in individuals with a prior advanced adenoma. In a
    randomized, placebo-controlled prevention trial the vaccine was immunogenic
    only in vaccine recipients but did not significantly reduce adenoma recurrence
    overall; a 38% absolute reduction was seen in the subset who mounted an immune
    response. It remains investigational.
  therapeutic_modality: VACCINE
  treatment_term:
    preferred_term: vaccination
    term:
      id: NCIT:C15346
      label: Vaccination
  target_mechanisms:
  - target: Adenoma-Carcinoma Sequence
    treatment_effect: INHIBITS
    description: >-
      Anti-MUC1 immunity is intended to eliminate MUC1-overexpressing adenomatous
      epithelium and reduce adenoma recurrence, intercepting the adenoma-carcinoma
      sequence; in the trial the vaccine did not reduce adenoma recurrence in the
      intention-to-treat population (aRR 0.83, 95% CI 0.60-1.14, P = 0.25), and the
      38% absolute reduction observed in immune responders was likewise not
      statistically significant (aRR 0.41, 95% CI 0.15-1.11, P = 0.08) —
      hypothesis-generating rather than confirmatory.
    evidence:
    - reference: PMID:36892581
      reference_title: "Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "a 38% absolute reduction in adenoma recurrence compared with placebo was observed in participants who had an immune response at week 12 and with the booster injection."
      explanation: Randomized-trial evidence of a hypothesis-generating signal — a
        38% absolute reduction in adenoma recurrence was observed only in immune
        responders and was not statistically significant (P = 0.08), with no effect
        in the intention-to-treat population (P = 0.25) — supporting a qualified,
        non-confirmatory INHIBITS edge on the adenoma-carcinoma sequence.
  evidence:
  - reference: PMID:36892581
    reference_title: "Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An immune response was observed only in vaccine recipients."
    explanation: Confirms the MUC1 peptide vaccine is immunogenic in the colorectal
      adenoma prevention setting.
- name: Encorafenib Plus Binimetinib and Cetuximab for BRAF V600E Disease
  description: Encorafenib, binimetinib, and cetuximab provide a targeted regimen for BRAF V600E-mutant metastatic colorectal cancer, pairing BRAF and MEK inhibition with EGFR blockade to suppress MAPK feedback signaling.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: encorafenib
      term:
        id: NCIT:C98283
        label: Encorafenib
    - preferred_term: binimetinib
      term:
        id: CHEBI:145371
        label: binimetinib
    - preferred_term: cetuximab
      term:
        id: NCIT:C1723
        label: Cetuximab
  evidence:
  - reference: DOI:10.1200/jco.22.01693
    reference_title: 'ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The positive BEACON colorectal cancer (CRC) safety lead-in,
      evaluating encorafenib + cetuximab + binimetinib in previously treated
      patients with BRAFV600E-mutated metastatic CRC (mCRC), prompted the
      design of the phase II ANCHOR CRC study (ClinicalTrails.gov identifier:
      NCT03693170 ).
    explanation: The phase II ANCHOR CRC study directly evaluates this BRAF/MEK/EGFR targeted combination in BRAF V600E-mutant metastatic CRC.
- name: Cetuximab for RAS Wild-Type Disease Stratified by APC Mutation Status
  description: Cetuximab combined with chemotherapy for RAS wild-type metastatic CRC shows improved outcomes in APC-mutant tumors. APC mutation status serves as a predictive biomarker, with APC-mutant tumors achieving higher response rates and longer overall survival compared to APC wild-type tumors, suggesting that Wnt pathway dysregulation influences EGFR inhibitor sensitivity.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: cetuximab
      term:
        id: NCIT:C1723
        label: Cetuximab
  evidence:
  - reference: PMID:42199488
    reference_title: 'The impact of APC mutation on the efficacy of anti-EGFR therapy in metastatic colorectal cancer with RAS wild type: a retrospective analysis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: partial response was achieved in 64 patients with APC-mutated tumors (85%) and 17 patients with APC wild type tumors (59%). There was a significant difference in the objective response rate (ORR) between patients with APC mutation and wild type (p-value of 0.003).
    explanation: This clinical study demonstrates APC mutation status as a predictive biomarker for cetuximab response in RAS wild-type disease, with significantly higher objective response rates in APC-mutant patients.
  - reference: PMID:42199488
    reference_title: 'The impact of APC mutation on the efficacy of anti-EGFR therapy in metastatic colorectal cancer with RAS wild type: a retrospective analysis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The median OS was not reached (95% CI, 31.5-NA) in patients with the APC mutation, whereas it was 37.3 months (95% CI, 23.4-NA) in those with APC-wild type tumors (p = 0.024).
    explanation: APC-mutant patients treated with cetuximab-containing chemotherapy show significantly longer median overall survival compared to APC wild-type patients.
datasets:
- accession: geo:GSE39582
  title: Gene expression Classification of Colon Cancer defines six molecular
    subtypes with distinct clinical, molecular and survival characteristics
    [Expression]
  description: >-
    Microarray dataset with colorectal cancer and non-tumoral mucosa samples
    used for molecular classification and outcome studies.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_types:
  - preferred_term: colon tissue
    tissue_term:
      preferred_term: colon
      term:
        id: UBERON:0001155
        label: colon
  sample_count: 462
  conditions:
  - colorectal cancer
  - non-tumoral colonic mucosa
  notes: >-
    Includes 443 colorectal cancer samples and 19 non-tumoral mucosa samples.
- accession: ega:EGAS00001002539
  title: Multi-region sequencing of metastatic colorectal cancer
  description: In order to reconstruct the evolutionary history of metastatic colorectal cancer, we performed whole-exome sequencing of 10 metastatic colorectal cancer patients for whom the primary tumor and matched distant metastases to the brain (n=10), liver (n=1), lung (n=1), as well as lymph node metastases (n=4) were available. For 6 of the 10 patients, multiple regions (n=2-5) of the primary tumor and distant metastases were sequenced.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Metastatic Colorectal Cancer"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001003568
  title: Multi-region sequencing of metastatic colorectal cancer
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: WES
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Metastatic Colorectal Cancer"); description-level mentions were not accepted. EGA study_type: Exome Sequencing. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001003573
  title: Multi-Region WES of Metastatic Colorectal Cancer
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Metastatic Colorectal Cancer"); description-level mentions were not accepted. EGA study_type: Cancer Genomics. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: dbgap:phs000790
  title: Comparative Analysis of Primary and Metastatic Colorectal Cancer
  description:  Molecular profiling for somatic mutations that predict response to anti-EGFR therapy in colorectal cancer (CRC) has become standard practice. However, abundant tissue from metastatic lesions is not always available from patients with metastatic CRC. Concerns involving genetic heterogeneity between primary and metastatic lesions have called into question the suitability of profiling primary tumors in patients with metastatic disease.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Metastatic Colorectal Cancer"). Retrieved 2026-08-02.
references:
- reference: DOI:10.1007/s00428-024-03746-3
  title: Molecular pathological classification of colorectal cancer—an update
  findings: []
- reference: DOI:10.1007/s12254-023-00893-2
  title: Molecular pathology of colorectal cancer
  findings: []
- reference: DOI:10.1038/s43018-024-00841-x
  title: Recapitulating the adenoma–carcinoma sequence by selection of four
    spontaneous oncogenic mutations in mismatch-repair-deficient human colon
    organoids
  findings: []
- reference: DOI:10.1186/s13053-024-00279-3
  title: Incidences of colorectal adenomas and cancers under colonoscopy
    surveillance suggest an accelerated “Big Bang” pathway to CRC in three of
    the four Lynch syndromes
  findings: []
- reference: DOI:10.2147/cmar.s481656
  title: 'Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic
    Strategies'
  findings: []
- reference: DOI:10.3389/fimmu.2025.1735873
  title: 'The metabolism-immune axis in colorectal cancer: remodeling the tumor microenvironment
    through metabolite signaling'
  findings: []
- reference: DOI:10.3390/cancers16081551
  title: Molecular Landscape and Therapeutic Strategies against Colorectal
    Cancer
  findings: []
- reference: DOI:10.3390/cancers16172967
  title: 'Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases:
    Risk Management and Surveillance Strategies'
  findings: []
- reference: PMID:11455558
  title: Clinical significance of E-cadherin-catenin complex expression in
    metastatic foci of colorectal carcinoma.
  findings: []
- reference: PMID:14685678
  title: '[Matrix metalloproteinases and colorectal cancer].'
  findings: []
- reference: PMID:29334918
  title: Colorectal cancer liver metastases - a population-based study on
    incidence, management and survival.
  findings: []
- reference: PMID:37499275
  title: The microbial genotoxin colibactin exacerbates mismatch repair
    mutations in colorectal tumors.
  findings: []
- reference: DOI:10.1001/jamanetworkopen.2024.52661
  title: Circulating Tumor DNA Testing in Curatively Resected Colorectal Cancer and Salvage Resection
  found_in:
  - Metastatic_Colorectal_Cancer-deep-research-falcon.md
  findings:
  - statement: Circulating Tumor DNA Testing in Curatively Resected Colorectal Cancer and Salvage Resection
    supporting_text: ImportanceSerial circulating tumor DNA (ctDNA) has emerged as a routine surveillance strategy for patients with resected colorectal cancer, but how serial ctDNA monitoring is associated with potential curative outcomes has not been formally assessed.ObjectiveTo examine whether there is a benefit of adding serial ctDNA assays to standard-of-care imaging surveillance for potential curative outcomes in patients with resected colorectal cancer.Design, Setting, and ParticipantsIn this single-center (City of Hope Comprehensive Cancer Center, Duarte, California), retrospective, case cohort study, patients with stage II to IV colorectal cancer underwent curative resection and were monitored with serial ctDNA assay and National Cancer Center Network (NCCN)–guided imaging surveillance from September 20, 2019, to April 3, 2024.
    evidence:
    - reference: DOI:10.1001/jamanetworkopen.2024.52661
      reference_title: Circulating Tumor DNA Testing in Curatively Resected Colorectal Cancer and Salvage Resection
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: ImportanceSerial circulating tumor DNA (ctDNA) has emerged as a routine surveillance strategy for patients with resected colorectal cancer, but how serial ctDNA monitoring is associated with potential curative outcomes has not been formally assessed.ObjectiveTo examine whether there is a benefit of adding serial ctDNA assays to standard-of-care imaging surveillance for potential curative outcomes in patients with resected colorectal cancer.Design, Setting, and ParticipantsIn this single-center (City of Hope Comprehensive Cancer Center, Duarte, California), retrospective, case cohort study, patients with stage II to IV colorectal cancer underwent curative resection and were monitored with serial ctDNA assay and National Cancer Center Network (NCCN)–guided imaging surveillance from September 20, 2019, to April 3, 2024.
      explanation: Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
- reference: DOI:10.1007/s12094-023-03309-z
  title: Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain
  found_in:
  - Metastatic_Colorectal_Cancer-deep-research-falcon.md
  findings:
  - statement: Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).
    supporting_text: Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).
    evidence:
    - reference: DOI:10.1007/s12094-023-03309-z
      reference_title: Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).
      explanation: Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
- reference: DOI:10.1038/s41591-023-02696-8
  title: 'Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial'
  found_in:
  - Metastatic_Colorectal_Cancer-deep-research-falcon.md
  findings:
  - statement: KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis.
    supporting_text: KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis.
    evidence:
    - reference: DOI:10.1038/s41591-023-02696-8
      reference_title: 'Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis.
      explanation: Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
- reference: DOI:10.1038/s41591-024-03254-6
  title: ctDNA-based molecular residual disease and survival in resectable colorectal cancer
  found_in:
  - Metastatic_Colorectal_Cancer-deep-research-falcon.md
  findings:
  - statement: ctDNA-based molecular residual disease and survival in resectable colorectal cancer
    supporting_text: ctDNA-based molecular residual disease and survival in resectable colorectal cancer
- reference: DOI:10.1038/s41598-024-54972-3
  title: 'Survival outcome and prognostic factors for early-onset and late-onset metastatic colorectal cancer: a population based study from SEER database'
  found_in:
  - Metastatic_Colorectal_Cancer-deep-research-falcon.md
  findings:
  - statement: Colorectal cancer is the third most common cancer worldwide and there has been a concerning increase in the incidence rate of colorectal cancer among individuals under the age of 50.
    supporting_text: Colorectal cancer is the third most common cancer worldwide and there has been a concerning increase in the incidence rate of colorectal cancer among individuals under the age of 50.
    evidence:
    - reference: DOI:10.1038/s41598-024-54972-3
      reference_title: 'Survival outcome and prognostic factors for early-onset and late-onset metastatic colorectal cancer: a population based study from SEER database'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Colorectal cancer is the third most common cancer worldwide and there has been a concerning increase in the incidence rate of colorectal cancer among individuals under the age of 50.
      explanation: Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
- reference: DOI:10.1158/1078-0432.ccr-23-3660
  title: Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
  found_in:
  - Metastatic_Colorectal_Cancer-deep-research-falcon.md
  findings:
  - statement: Minimal residual disease (MRD) detection can identify the recurrence in patients with colorectal cancer (CRC) following definitive treatment.
    supporting_text: Minimal residual disease (MRD) detection can identify the recurrence in patients with colorectal cancer (CRC) following definitive treatment.
    evidence:
    - reference: DOI:10.1158/1078-0432.ccr-23-3660
      reference_title: Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: Minimal residual disease (MRD) detection can identify the recurrence in patients with colorectal cancer (CRC) following definitive treatment.
      explanation: Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
- reference: DOI:10.1200/jco.22.01693
  title: 'ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer'
  found_in:
  - Metastatic_Colorectal_Cancer-deep-research-falcon.md
  findings:
  - statement: 'ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer'
    supporting_text: 'The positive BEACON colorectal cancer (CRC) safety lead-in, evaluating encorafenib + cetuximab + binimetinib in previously treated patients with BRAFV600E-mutated metastatic CRC (mCRC), prompted the design of the phase II ANCHOR CRC study (ClinicalTrails.gov identifier: NCT03693170 ).'
    evidence:
    - reference: DOI:10.1200/jco.22.01693
      reference_title: 'ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'The positive BEACON colorectal cancer (CRC) safety lead-in, evaluating encorafenib + cetuximab + binimetinib in previously treated patients with BRAFV600E-mutated metastatic CRC (mCRC), prompted the design of the phase II ANCHOR CRC study (ClinicalTrails.gov identifier: NCT03693170 ).'
      explanation: Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
- reference: DOI:10.1200/po.23.00127
  title: Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer
  found_in:
  - Metastatic_Colorectal_Cancer-deep-research-falcon.md
  findings:
  - statement: Recurrence after curative-intent treatment occurs in 20%-50% of patients with stage II-IV colorectal cancer (CRC), underscoring the need for early detection of minimal residual disease (MRD) using circulating tumor DNA (ctDNA).
    supporting_text: Recurrence after curative-intent treatment occurs in 20%-50% of patients with stage II-IV colorectal cancer (CRC), underscoring the need for early detection of minimal residual disease (MRD) using circulating tumor DNA (ctDNA).
    evidence:
    - reference: DOI:10.1200/po.23.00127
      reference_title: Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Recurrence after curative-intent treatment occurs in 20%-50% of patients with stage II-IV colorectal cancer (CRC), underscoring the need for early detection of minimal residual disease (MRD) using circulating tumor DNA (ctDNA).
      explanation: Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
- reference: DOI:10.3390/cancers16112004
  title: 'Survival Analysis of Metastatic Early-Onset Colorectal Cancer Compared to Metastatic Average-Onset Colorectal Cancer: A SEER Database Analysis'
  found_in:
  - Metastatic_Colorectal_Cancer-deep-research-falcon.md
  findings:
  - statement: Early-onset colorectal cancer (EO-CRC) is defined as colorectal cancer diagnosed before the age of 50 years, and its incidence has been increasing over the last decade, now accounting for 10% of all new CRC diagnoses.
    supporting_text: Early-onset colorectal cancer (EO-CRC) is defined as colorectal cancer diagnosed before the age of 50 years, and its incidence has been increasing over the last decade, now accounting for 10% of all new CRC diagnoses.
    evidence:
    - reference: DOI:10.3390/cancers16112004
      reference_title: 'Survival Analysis of Metastatic Early-Onset Colorectal Cancer Compared to Metastatic Average-Onset Colorectal Cancer: A SEER Database Analysis'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Early-onset colorectal cancer (EO-CRC) is defined as colorectal cancer diagnosed before the age of 50 years, and its incidence has been increasing over the last decade, now accounting for 10% of all new CRC diagnoses.
      explanation: Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
- reference: DOI:10.3390/cancers16162796
  title: 'Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review'
  found_in:
  - Metastatic_Colorectal_Cancer-deep-research-falcon.md
  findings:
  - statement: Colorectal cancer (CRC) remains the second leading cause of cancer-related mortality worldwide.
    supporting_text: Colorectal cancer (CRC) remains the second leading cause of cancer-related mortality worldwide.
    evidence:
    - reference: DOI:10.3390/cancers16162796
      reference_title: 'Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Colorectal cancer (CRC) remains the second leading cause of cancer-related mortality worldwide.
      explanation: Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
- reference: DOI:10.3390/cancers16223870
  title: 'Precision Medicine for Metastatic Colorectal Cancer: Where Do We Stand?'
  found_in:
  - Metastatic_Colorectal_Cancer-deep-research-falcon.md
  findings:
  - statement: Metastatic colorectal cancer is a leading cause of cancer-related death across the world.
    supporting_text: Metastatic colorectal cancer is a leading cause of cancer-related death across the world.
    evidence:
    - reference: DOI:10.3390/cancers16223870
      reference_title: 'Precision Medicine for Metastatic Colorectal Cancer: Where Do We Stand?'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Metastatic colorectal cancer is a leading cause of cancer-related death across the world.
      explanation: Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
- reference: DOI:10.3390/cancers16233928
  title: 'Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review'
  found_in:
  - Metastatic_Colorectal_Cancer-deep-research-falcon.md
  findings:
  - statement: Colorectal cancer (CRC) remains a significant global health burden, necessitating a thorough understanding of prognostic and predictive factors to enhance patient outcomes.
    supporting_text: Colorectal cancer (CRC) remains a significant global health burden, necessitating a thorough understanding of prognostic and predictive factors to enhance patient outcomes.
    evidence:
    - reference: DOI:10.3390/cancers16233928
      reference_title: 'Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Colorectal cancer (CRC) remains a significant global health burden, necessitating a thorough understanding of prognostic and predictive factors to enhance patient outcomes.
      explanation: Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
- reference: DOI:10.3390/medsci12030047
  title: Survival Analysis, Clinical Characteristics, and Predictors of Cerebral Metastases in Patients with Colorectal Cancer
  found_in:
  - Metastatic_Colorectal_Cancer-deep-research-falcon.md
  findings:
  - statement: Colorectal cancer (CRC) is the third most common cancer globally and a leading cause of cancer-related deaths.
    supporting_text: Colorectal cancer (CRC) is the third most common cancer globally and a leading cause of cancer-related deaths.
    evidence:
    - reference: DOI:10.3390/medsci12030047
      reference_title: Survival Analysis, Clinical Characteristics, and Predictors of Cerebral Metastases in Patients with Colorectal Cancer
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Colorectal cancer (CRC) is the third most common cancer globally and a leading cause of cancer-related deaths.
      explanation: Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
- reference: DOI:10.6004/jnccn.2024.0029
  title: Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
  found_in:
  - Metastatic_Colorectal_Cancer-deep-research-falcon.md
  findings:
  - statement: Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States.
    supporting_text: Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States.
    evidence:
    - reference: DOI:10.6004/jnccn.2024.0029
      reference_title: Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States.
      explanation: Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
genetic:
- name: APC
  gene_term:
    preferred_term: APC
    term:
      id: hgnc:583
      label: APC
  association: Somatic loss of function
  notes: APC inactivation is the canonical initiator of WNT pathway activation in colorectal carcinogenesis and metastatic progression.
- name: KRAS
  gene_term:
    preferred_term: KRAS
    term:
      id: hgnc:6407
      label: KRAS
  association: Somatic activating mutation
  notes: KRAS mutations promote metastatic fitness, EGFR resistance, and inferior survival.
- name: BRAF
  gene_term:
    preferred_term: BRAF
    term:
      id: hgnc:1097
      label: BRAF
  association: Somatic activating mutation
  notes: BRAF, especially V600E, is linked to aggressive metastatic behavior and poor prognosis.
- name: Mismatch repair deficiency / MSI-high state
  association: Hypermutator phenotype
  notes: MSI-high tumors have distinct immune biology and may respond better to checkpoint blockade despite advanced disease.
environmental:
- name: Obesity
  notes: Obesity increases colorectal cancer risk and can reinforce inflammatory programs linked to metastatic progression.
  evidence:
  - reference: PMID:18086756
    reference_title: "Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the estimated relative risk of colorectal cancer was 1.19 [95% confidence interval (95% CI), 1.11-1.29], comparing obese (BMI > or = 30 kg/m(2)) with normal weight (BMI <25 kg/m(2)) people"
    explanation: Meta-analysis of 31 studies quantifies obesity's association with colorectal cancer risk.
- name: Alcohol exposure
  exposure_term:
    preferred_term: exposure to alcohol consumption
    term:
      id: ECTO:0001082
      label: exposure to alcohol consumption
  notes: Alcohol contributes to colorectal cancer risk and often coexists with metabolic and inflammatory exposures.
  evidence:
  - reference: PMID:21307158
    reference_title: "Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The RRs were 1.21 [95% confidence interval (CI) 1.13-1.28] for moderate and 1.52 (95% CI 1.27-1.81) for heavy (≥4 drinks/day) alcohol drinking"
    explanation: Dose-response meta-analysis quantifies alcohol's association with colorectal cancer risk.
📚

References & Deep Research

References

26
DOI:10.1007/s00428-024-03746-3
Molecular pathological classification of colorectal cancer—an update
No top-level findings curated for this source.
DOI:10.1007/s12254-023-00893-2
Molecular pathology of colorectal cancer
No top-level findings curated for this source.
DOI:10.1038/s43018-024-00841-x
Recapitulating the adenoma–carcinoma sequence by selection of four spontaneous oncogenic mutations in mismatch-repair-deficient human colon organoids
No top-level findings curated for this source.
DOI:10.1186/s13053-024-00279-3
Incidences of colorectal adenomas and cancers under colonoscopy surveillance suggest an accelerated “Big Bang” pathway to CRC in three of the four Lynch syndromes
No top-level findings curated for this source.
DOI:10.2147/cmar.s481656
Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic Strategies
No top-level findings curated for this source.
DOI:10.3389/fimmu.2025.1735873
The metabolism-immune axis in colorectal cancer: remodeling the tumor microenvironment through metabolite signaling
No top-level findings curated for this source.
DOI:10.3390/cancers16081551
Molecular Landscape and Therapeutic Strategies against Colorectal Cancer
No top-level findings curated for this source.
DOI:10.3390/cancers16172967
Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: Risk Management and Surveillance Strategies
No top-level findings curated for this source.
PMID:11455558
Clinical significance of E-cadherin-catenin complex expression in metastatic foci of colorectal carcinoma.
No top-level findings curated for this source.
PMID:14685678
[Matrix metalloproteinases and colorectal cancer].
No top-level findings curated for this source.
PMID:29334918
Colorectal cancer liver metastases - a population-based study on incidence, management and survival.
No top-level findings curated for this source.
PMID:37499275
The microbial genotoxin colibactin exacerbates mismatch repair mutations in colorectal tumors.
No top-level findings curated for this source.
DOI:10.1001/jamanetworkopen.2024.52661
Circulating Tumor DNA Testing in Curatively Resected Colorectal Cancer and Salvage Resection
1 finding
Circulating Tumor DNA Testing in Curatively Resected Colorectal Cancer and Salvage Resection
"ImportanceSerial circulating tumor DNA (ctDNA) has emerged as a routine surveillance strategy for patients with resected colorectal cancer, but how serial ctDNA monitoring is associated with potential curative outcomes has not been formally assessed.ObjectiveTo examine whether there is a benefit..."
Show evidence (1 reference)
DOI:10.1001/jamanetworkopen.2024.52661 SUPPORT Human Clinical
"ImportanceSerial circulating tumor DNA (ctDNA) has emerged as a routine surveillance strategy for patients with resected colorectal cancer, but how serial ctDNA monitoring is associated with potential curative outcomes has not been formally assessed.ObjectiveTo examine whether there is a benefit..."
Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
DOI:10.1007/s12094-023-03309-z
Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain
1 finding
Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).
"Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H)."
Show evidence (1 reference)
DOI:10.1007/s12094-023-03309-z SUPPORT Human Clinical
"Clinical practice guidelines recommend that all patients with metastatic colorectal cancer (mCRC) should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H)."
Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
DOI:10.1038/s41591-023-02696-8
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
1 finding
KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis.
"KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis."
Show evidence (1 reference)
DOI:10.1038/s41591-023-02696-8 SUPPORT Human Clinical
"KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis."
Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
DOI:10.1038/s41591-024-03254-6
ctDNA-based molecular residual disease and survival in resectable colorectal cancer
1 finding
ctDNA-based molecular residual disease and survival in resectable colorectal cancer
"ctDNA-based molecular residual disease and survival in resectable colorectal cancer"
DOI:10.1038/s41598-024-54972-3
Survival outcome and prognostic factors for early-onset and late-onset metastatic colorectal cancer: a population based study from SEER database
1 finding
Colorectal cancer is the third most common cancer worldwide and there has been a concerning increase in the incidence rate of colorectal cancer among individuals under the age of 50.
"Colorectal cancer is the third most common cancer worldwide and there has been a concerning increase in the incidence rate of colorectal cancer among individuals under the age of 50."
Show evidence (1 reference)
DOI:10.1038/s41598-024-54972-3 SUPPORT Human Clinical
"Colorectal cancer is the third most common cancer worldwide and there has been a concerning increase in the incidence rate of colorectal cancer among individuals under the age of 50."
Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
DOI:10.1158/1078-0432.ccr-23-3660
Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
1 finding
Minimal residual disease (MRD) detection can identify the recurrence in patients with colorectal cancer (CRC) following definitive treatment.
"Minimal residual disease (MRD) detection can identify the recurrence in patients with colorectal cancer (CRC) following definitive treatment."
Show evidence (1 reference)
DOI:10.1158/1078-0432.ccr-23-3660 SUPPORT Computational
"Minimal residual disease (MRD) detection can identify the recurrence in patients with colorectal cancer (CRC) following definitive treatment."
Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
DOI:10.1200/jco.22.01693
ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer
1 finding
ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer
"The positive BEACON colorectal cancer (CRC) safety lead-in, evaluating encorafenib + cetuximab + binimetinib in previously treated patients with BRAFV600E-mutated metastatic CRC (mCRC), prompted the design of the phase II ANCHOR CRC study (ClinicalTrails.gov identifier: NCT03693170 )."
Show evidence (1 reference)
DOI:10.1200/jco.22.01693 SUPPORT Human Clinical
"The positive BEACON colorectal cancer (CRC) safety lead-in, evaluating encorafenib + cetuximab + binimetinib in previously treated patients with BRAFV600E-mutated metastatic CRC (mCRC), prompted the design of the phase II ANCHOR CRC study (ClinicalTrails.gov identifier: NCT03693170 )."
Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
DOI:10.1200/po.23.00127
Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer
1 finding
Recurrence after curative-intent treatment occurs in 20%-50% of patients with stage II-IV colorectal cancer (CRC), underscoring the need for early detection of minimal residual disease (MRD) using circulating tumor DNA (ctDNA).
"Recurrence after curative-intent treatment occurs in 20%-50% of patients with stage II-IV colorectal cancer (CRC), underscoring the need for early detection of minimal residual disease (MRD) using circulating tumor DNA (ctDNA)."
Show evidence (1 reference)
DOI:10.1200/po.23.00127 SUPPORT Human Clinical
"Recurrence after curative-intent treatment occurs in 20%-50% of patients with stage II-IV colorectal cancer (CRC), underscoring the need for early detection of minimal residual disease (MRD) using circulating tumor DNA (ctDNA)."
Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
DOI:10.3390/cancers16112004
Survival Analysis of Metastatic Early-Onset Colorectal Cancer Compared to Metastatic Average-Onset Colorectal Cancer: A SEER Database Analysis
1 finding
Early-onset colorectal cancer (EO-CRC) is defined as colorectal cancer diagnosed before the age of 50 years, and its incidence has been increasing over the last decade, now accounting for 10% of all new CRC diagnoses.
"Early-onset colorectal cancer (EO-CRC) is defined as colorectal cancer diagnosed before the age of 50 years, and its incidence has been increasing over the last decade, now accounting for 10% of all new CRC diagnoses."
Show evidence (1 reference)
DOI:10.3390/cancers16112004 SUPPORT Human Clinical
"Early-onset colorectal cancer (EO-CRC) is defined as colorectal cancer diagnosed before the age of 50 years, and its incidence has been increasing over the last decade, now accounting for 10% of all new CRC diagnoses."
Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
DOI:10.3390/cancers16162796
Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
1 finding
Colorectal cancer (CRC) remains the second leading cause of cancer-related mortality worldwide.
"Colorectal cancer (CRC) remains the second leading cause of cancer-related mortality worldwide."
Show evidence (1 reference)
DOI:10.3390/cancers16162796 SUPPORT Human Clinical
"Colorectal cancer (CRC) remains the second leading cause of cancer-related mortality worldwide."
Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
DOI:10.3390/cancers16223870
Precision Medicine for Metastatic Colorectal Cancer: Where Do We Stand?
1 finding
Metastatic colorectal cancer is a leading cause of cancer-related death across the world.
"Metastatic colorectal cancer is a leading cause of cancer-related death across the world."
Show evidence (1 reference)
DOI:10.3390/cancers16223870 SUPPORT Human Clinical
"Metastatic colorectal cancer is a leading cause of cancer-related death across the world."
Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
DOI:10.3390/cancers16233928
Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review
1 finding
Colorectal cancer (CRC) remains a significant global health burden, necessitating a thorough understanding of prognostic and predictive factors to enhance patient outcomes.
"Colorectal cancer (CRC) remains a significant global health burden, necessitating a thorough understanding of prognostic and predictive factors to enhance patient outcomes."
Show evidence (1 reference)
DOI:10.3390/cancers16233928 SUPPORT Other
"Colorectal cancer (CRC) remains a significant global health burden, necessitating a thorough understanding of prognostic and predictive factors to enhance patient outcomes."
Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
DOI:10.3390/medsci12030047
Survival Analysis, Clinical Characteristics, and Predictors of Cerebral Metastases in Patients with Colorectal Cancer
1 finding
Colorectal cancer (CRC) is the third most common cancer globally and a leading cause of cancer-related deaths.
"Colorectal cancer (CRC) is the third most common cancer globally and a leading cause of cancer-related deaths."
Show evidence (1 reference)
DOI:10.3390/medsci12030047 SUPPORT Human Clinical
"Colorectal cancer (CRC) is the third most common cancer globally and a leading cause of cancer-related deaths."
Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.
DOI:10.6004/jnccn.2024.0029
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
1 finding
Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States.
"Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States."
Show evidence (1 reference)
DOI:10.6004/jnccn.2024.0029 SUPPORT Human Clinical
"Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States."
Deep research cited this publication as relevant literature for Metastatic Colorectal Cancer.

Deep Research

2
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 19 citations 2026-01-31T17:28:07.511631

Disease Pathophysiology Research Report

Target Disease

  • Disease Name: Colon Adenocarcinoma
  • MONDO ID: MONDO:0004992 (colon adenocarcinoma)
  • Category: Cancer

Pathophysiology description (current understanding)

Colon adenocarcinoma arises through distinct but overlapping molecular routes that converge on deregulated signaling, altered cell states, epigenetic remodeling, and reprogrammed ecosystems. Three primary mechanisms of genomic/epigenomic instability predominate: chromosomal instability (CIN; ~70–84% of sporadic CRC), microsatellite instability (MSI; ~13–16%), and the CpG island methylator phenotype (CIMP) that underlies the serrated neoplasia pathway (~15–30%) and frequently co-occurs with BRAF V600E and MLH1 promoter hypermethylation (proximal, mucinous, lymphocyte-rich tumors) (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4, yang2024molecularcomplexityof pages 6-8). The classical adenoma–carcinoma sequence typically begins with APC loss and WNT activation, followed by subclonal selection of KRAS/PIK3CA, and later disruption of TP53 and SMAD4; MSI tumors emerge from defective mismatch repair via germline MMR variants or sporadic MLH1 methylation; serrated lesions progress through MAPK activation (BRAF), diffuse CpG methylation, and often MLH1 silencing leading to MSI (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4, yang2024molecularcomplexityof pages 6-8).

Dysregulated pathways include WNT/β-catenin (APC/AXIN1/AXIN2/CTNNB1), RAS–RAF–MEK–ERK (KRAS/NRAS/BRAF), PI3K/AKT/mTOR (PIK3CA), TGF-β/BMP (SMAD4, ACVR2A, BMPR2), and the p53 axis; organoid modeling in 2024 recapitulated stepwise selection across WNT, EGFR/MAPK, BMP, and p53 programs in mismatch-repair–deficient human colon epithelium, producing quadruple-pathway mutant clones that form tumors in vivo (mizutani2024recapitulatingtheadenoma–carcinoma pages 8-10). Transcriptomic taxonomies have evolved from bulk-derived CMS (CMS1 immune/MSI; CMS2 canonical/WNT; CMS3 metabolic; CMS4 mesenchymal/EMT) toward intrinsic (CRIS) and pathway-derived subtypes that separate neoplastic-intrinsic biology from microenvironmental signals, refining prognostic and predictive stratification (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4).

The tumor microenvironment (TME) and microbiome modulate progression and therapy response. High stromal/EMT signaling (CMS4) portends poor outcome; MSI/CMS1 exhibits immune activation and checkpoint sensitivity. Dysbiosis with Fusobacterium nucleatum and other species is associated with immune evasion and worse survival; short-chain fatty acids (SCFAs) such as butyrate and acetate and lactate from tumor glycolysis shape epigenetic states and immunity, integrating metabolism–immune crosstalk (noack2023molecularpathologyof pages 3-4, hu2025themetabolismimmuneaxis pages 2-3, yang2024molecularcomplexityof pages 6-8). Recent single-cell and spatial analyses, and classification refinements, highlight malignant cell programs, fibroblast–tumor niches, and immune micro-niches driving heterogeneity and outcome, while deconvolving tumor-intrinsic from stromal signals (dunne2024molecularpathologicalclassification pages 1-2, mizutani2024recapitulatingtheadenoma–carcinoma pages 8-10).

Gene/protein annotations (HGNC) and ontology terms

  • Genes/proteins (HGNC): APC, CTNNB1, AXIN1/AXIN2, KRAS, NRAS, BRAF, PIK3CA, TP53, SMAD4, RNF43, ACVR2A, BMPR2, MLH1, MSH2, MSH6, PMS2, POLE, POLD1 (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4, mizutani2024recapitulatingtheadenoma–carcinoma pages 8-10, yang2024molecularcomplexityof pages 6-8).
  • GO Biological Processes: Wnt signaling pathway; MAPK cascade; PI3K signaling; TGF-β receptor signaling pathway; DNA mismatch repair; chromosomal instability; epithelial–mesenchymal transition; stem cell population maintenance; cell proliferation; glycolytic process; glutamine metabolic process; immune response; extracellular matrix organization (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4, yang2024molecularcomplexityof pages 6-8).
  • CL Cell Types: intestinal epithelial cell; intestinal LGR5+ stem cell; cancer-associated fibroblast; CD8+ T cell; B cell/plasma cell; macrophage/tumor-associated macrophage; dendritic cell (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4).
  • UBERON Anatomy: colon; colon mucosa; colonic crypt; proximal colon; distal colon (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4).
  • CHEBI Chemical Entities: butyrate; acetate; lactate (hu2025themetabolismimmuneaxis pages 2-3, yang2024molecularcomplexityof pages 6-8).

Required Information

1) Core Pathophysiology - Primary mechanisms: CIN with widespread copy-number alterations and early APC/WNT disruption; MSI via dMMR (germline MMR variants or sporadic MLH1 hypermethylation); CIMP/serrated route with BRAF-driven MAPK activation and diffuse promoter hypermethylation often culminating in MSI (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4, yang2024molecularcomplexityof pages 6-8). - Dysregulated pathways: WNT/β-catenin, RAS–RAF–MEK–ERK, PI3K/AKT/mTOR, TGF-β/BMP, and p53; organoid selection experiments demonstrate sequential acquisition and functional cooperation of these axes in MMR-deficient epithelium (mizutani2024recapitulatingtheadenoma–carcinoma pages 8-10). - Cellular processes: stemness transitions (crypt LGR5+ vs regenerative ANXA1+), EMT and stromal activation (CMS4), proliferation and cell-cycle dysregulation, impaired DNA repair in MSI, and metabolic rewiring toward glycolysis, glutaminolysis, and lipid metabolism (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4, yang2024molecularcomplexityof pages 6-8).

2) Key Molecular Players - Genes/Proteins: APC, CTNNB1, RNF43 (WNT); KRAS, NRAS, BRAF (MAPK); PIK3CA (PI3K); TP53; SMAD4 (TGF-β); ACVR2A/BMPR2 (BMP); MLH1/MSH2/MSH6/PMS2 (MMR); POLE/POLD1 (ultramutated subset) (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4, mizutani2024recapitulatingtheadenoma–carcinoma pages 8-10, yang2024molecularcomplexityof pages 6-8). - Chemical Entities: SCFAs (butyrate, acetate) influencing epigenetics and immunity; lactate from aerobic glycolysis modulating TME acidity and immune suppression (hu2025themetabolismimmuneaxis pages 2-3, yang2024molecularcomplexityof pages 6-8). - Cell Types: neoplastic colon epithelial cells; LGR5+ stem cells; cancer-associated fibroblasts; infiltrating lymphocytes (CD8+ T cells, B/plasma cells); macrophages/TAMs; dendritic cells (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4). - Anatomical Locations: colonic crypt base; proximal colon (serrated/MSI/CIMP predominant); distal colon (CIN/CMS2 enriched) (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4).

3) Biological Processes (for GO annotation) - Signaling: Wnt signaling; MAPK cascade; PI3K/AKT signaling; TGF-β/BMP signaling; p53-mediated apoptosis and DNA damage response (dunne2024molecularpathologicalclassification pages 1-2, mizutani2024recapitulatingtheadenoma–carcinoma pages 8-10). - DNA repair/genomic stability: DNA mismatch repair; replication proofreading; regulation of chromosomal segregation (noack2023molecularpathologyof pages 3-4, yang2024molecularcomplexityof pages 6-8). - Cellular responses: epithelial–mesenchymal transition; stem cell population maintenance; response to oxidative stress/inflammation; immune activation/suppression (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4). - Metabolic processes: glycolytic process; lactate metabolic process; glutamine metabolic process; lipid biosynthetic process (yang2024molecularcomplexityof pages 6-8). - Transport/ECM: extracellular matrix organization; cell–cell adhesion; secretion and uptake of metabolites (noack2023molecularpathologyof pages 3-4, yang2024molecularcomplexityof pages 6-8).

4) Cellular Components - Cellular locations: plasma membrane receptors (EGFR, TGF-β receptors), cytosolic signaling complexes (MAPK, PI3K), nucleus (TCF/LEF–β-catenin transcription; p53), chromatin (epigenetic regulation), mitochondria (metabolic reprogramming), extracellular matrix and stromal compartments (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4).

5) Disease Progression - Sequence: normal mucosa → early adenoma (APC/WNT) → intermediate adenoma (KRAS/PIK3CA) → late adenoma/carcinoma (TP53, SMAD4; CIN accumulation); serrated route: hyperplastic/SSL → BRAF V600E + CIMP → MLH1 methylation → MSI carcinoma; MSI tumors display hypermutation and dense immune infiltration; organoid evidence shows that in dMMR epithelium, stepwise selection across WNT, BMP, MAPK, and p53 axes yields tumorigenic clones (noack2023molecularpathologyof pages 3-4, yang2024molecularcomplexityof pages 6-8, mizutani2024recapitulatingtheadenoma–carcinoma pages 8-10). In Lynch syndrome, surveillance data suggest accelerated “Big Bang”-like emergence from dMMR crypts in several MMR genotypes (brandaleone2024hereditarycolorectalcancer pages 5-6).

6) Phenotypic Manifestations (HP terms) - Colorectal polyposis/adenomas (HP:0006771), right-sided colonic carcinoma (HP:0030068), mucinous adenocarcinoma phenotype, tumor-infiltrating lymphocytosis (HP:0030057), microsatellite instability phenotype, poor differentiation in subsets, and stromal-rich mesenchymal tumors with aggressive course (CMS4) (noack2023molecularpathologyof pages 3-4, yang2024molecularcomplexityof pages 6-8). MSI tumors often show better baseline prognosis but distinct chemotherapy responsiveness and immunotherapy sensitivity (noack2023molecularpathologyof pages 3-4).

Current applications and real-world implementations

  • Molecular classification guides therapy: MSI-H/dMMR status predicts response to PD-1 blockade; MAPK-targeted regimens (e.g., BRAF V600E combination strategies) reflect pathway biology; KRAS mutational status drives anti-EGFR resistance and informs targeted trial designs (noack2023molecularpathologyof pages 3-4, patel2024molecularlandscapeand pages 6-8). Tumor transcriptomic stratification (CMS/CRIS) is being refined to disentangle TME versus tumor-intrinsic signals for prognosis and treatment selection (dunne2024molecularpathologicalclassification pages 1-2).

Expert opinions and analysis

  • 2024 reviews emphasize integrating bulk, single-cell, and spatial data to capture intra-/inter-tumor heterogeneity and to operationalize classifications that more accurately reflect tumor-intrinsic biology while acknowledging stromal/immune determinants of outcome (dunne2024molecularpathologicalclassification pages 1-2). MSI/CIMP biology continues to underpin biomarker-driven immunotherapy, while CIN/CMS4 biology underlines the need to target EMT/stroma and metabolism, including lactate-mediated immune suppression and glutamine dependence (noack2023molecularpathologyof pages 3-4, yang2024molecularcomplexityof pages 6-8).

Relevant statistics and data

  • Estimated route prevalence: CIN ~70–84% of sporadic CRC; MSI ~13–16% overall with ~3–4% hereditary; CIMP/serrated ~15–30% and strongly associated with BRAF V600E and MLH1 hypermethylation (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4, yang2024molecularcomplexityof pages 6-8). Microbiome: high Fusobacterium nucleatum abundance is associated with increased mortality risk; metabolic pathway alterations (glycolysis, glutaminolysis, lipid synthesis) are recurrent across CRC subtypes (hu2025themetabolismimmuneaxis pages 2-3, yang2024molecularcomplexityof pages 6-8).

Evidence items with PMIDs/DOIs/URLs and dates

  • Dunne PD, Arends MJ. Molecular pathological classification of colorectal cancer—an update. Virchows Archiv. 2024 Feb;484:273–285. doi:10.1007/s00428-024-03746-3. URL: https://doi.org/10.1007/s00428-024-03746-3 (dunne2024molecularpathologicalclassification pages 1-2).
  • Noack P, Langer R. Molecular pathology of colorectal cancer. memo. 2023 Apr;16:116–121. doi:10.1007/s12254-023-00893-2. URL: https://doi.org/10.1007/s12254-023-00893-2 (noack2023molecularpathologyof pages 3-4).
  • Patel A, Gulhati P. Molecular Landscape and Therapeutic Strategies against Colorectal Cancer. Cancers. 2024 Apr;16:1551. doi:10.3390/cancers16081551. URL: https://doi.org/10.3390/cancers16081551 (patel2024molecularlandscapeand pages 6-8).
  • Yang Z et al. Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic Strategies. Cancer Manag Res. 2024 Oct;16:1389–1403. doi:10.2147/CMAR.S481656. URL: https://doi.org/10.2147/cmar.s481656 (yang2024molecularcomplexityof pages 6-8).
  • Mizutani T et al. Recapitulating the adenoma–carcinoma sequence by selection of four spontaneous oncogenic mutations in mismatch-repair-deficient human colon organoids. Nature Cancer. 2024 Nov;5:1852–1867. doi:10.1038/s43018-024-00841-x. URL: https://doi.org/10.1038/s43018-024-00841-x (mizutani2024recapitulatingtheadenoma–carcinoma pages 8-10).
  • Møller P et al. Incidences under colonoscopy surveillance suggest an accelerated “Big Bang” pathway to CRC in Lynch syndromes. Hered Cancer Clin Pract. 2024 May;22. doi:10.1186/s13053-024-00279-3. URL: https://doi.org/10.1186/s13053-024-00279-3 (brandaleone2024hereditarycolorectalcancer pages 5-6).

Closing synthesis

Colon adenocarcinoma is best conceptualized as a set of evolutionary routes—CIN, MSI/CIMP, and serrated—with shared convergence on a limited set of pathways (WNT, MAPK, PI3K, TGF-β, p53) and recurrent cellular programs (stemness, EMT, metabolic rewiring). Recent organoid and single-cell/spatial studies sharpen the mechanistic sequence and reveal how tumor-intrinsic programs interface with fibroblast and immune niches to shape prognosis and therapeutic vulnerabilities. These integrated insights provide a framework for ontology-grounded knowledge bases and for aligning biomarkers with targeted, immunologic, and metabolism-directed interventions (dunne2024molecularpathologicalclassification pages 1-2, noack2023molecularpathologyof pages 3-4, mizutani2024recapitulatingtheadenoma–carcinoma pages 8-10).

References

  1. (dunne2024molecularpathologicalclassification pages 1-2): Philip D. Dunne and Mark J. Arends. Molecular pathological classification of colorectal cancer—an update. Virchows Archiv, 484:273-285, Feb 2024. URL: https://doi.org/10.1007/s00428-024-03746-3, doi:10.1007/s00428-024-03746-3. This article has 65 citations and is from a peer-reviewed journal.

  2. (noack2023molecularpathologyof pages 3-4): Petar Noack and Rupert Langer. Molecular pathology of colorectal cancer. memo - Magazine of European Medical Oncology, 16:116-121, Apr 2023. URL: https://doi.org/10.1007/s12254-023-00893-2, doi:10.1007/s12254-023-00893-2. This article has 13 citations.

  3. (yang2024molecularcomplexityof pages 6-8): Zhengdong Yang, Xinyang Wang, Huiying Zhou, Minghan Jiang, Jinghui Wang, and Bowen Sui. Molecular complexity of colorectal cancer: pathways, biomarkers, and therapeutic strategies. Cancer Management and Research, 16:1389-1403, Oct 2024. URL: https://doi.org/10.2147/cmar.s481656, doi:10.2147/cmar.s481656. This article has 19 citations and is from a peer-reviewed journal.

  4. (mizutani2024recapitulatingtheadenoma–carcinoma pages 8-10): Tomohiro Mizutani, Matteo Boretto, Sangho Lim, Jarno Drost, Diego Montiel González, Rurika Oka, Maarten H. Geurts, Harry Begthel, Jeroen Korving, Johan H. van Es, Ruben van Boxtel, and Hans Clevers. Recapitulating the adenoma–carcinoma sequence by selection of four spontaneous oncogenic mutations in mismatch-repair-deficient human colon organoids. Nature Cancer, 5:1852-1867, Nov 2024. URL: https://doi.org/10.1038/s43018-024-00841-x, doi:10.1038/s43018-024-00841-x. This article has 14 citations and is from a highest quality peer-reviewed journal.

  5. (hu2025themetabolismimmuneaxis pages 2-3): Shaofan Hu, Hui Heng, Fang Yang, Meng Wang, Guoxiang Liu, Yuancai Xiang, and Hongming Miao. The metabolism-immune axis in colorectal cancer: remodeling the tumor microenvironment through metabolite signaling. Frontiers in Immunology, Dec 2025. URL: https://doi.org/10.3389/fimmu.2025.1735873, doi:10.3389/fimmu.2025.1735873. This article has 0 citations and is from a peer-reviewed journal.

  6. (brandaleone2024hereditarycolorectalcancer pages 5-6): Luca Brandaleone, Arianna Dal Buono, Roberto Gabbiadini, Giacomo Marcozzi, Davide Polverini, Michele Carvello, Antonino Spinelli, Cesare Hassan, Alessandro Repici, Cristina Bezzio, and Alessandro Armuzzi. Hereditary colorectal cancer syndromes and inflammatory bowel diseases: risk management and surveillance strategies. Cancers, 16:2967, Aug 2024. URL: https://doi.org/10.3390/cancers16172967, doi:10.3390/cancers16172967. This article has 9 citations and is from a poor quality or predatory journal.

  7. (patel2024molecularlandscapeand pages 6-8): Aakash Patel and Pat Gulhati. Molecular landscape and therapeutic strategies against colorectal cancer. Cancers, 16:1551, Apr 2024. URL: https://doi.org/10.3390/cancers16081551, doi:10.3390/cancers16081551. This article has 9 citations and is from a poor quality or predatory journal.

OpenAI ▸
Target Disease
o3-deep-research-2025-06-26 126 citations 2026-02-01T09:56:10.182192

Target Disease

  • Disease Name: Colon Adenocarcinoma
  • MONDO ID: MONDO:0005401 (colonic neoplasm; specific subclass for colon adenocarcinoma)
  • Category: Cancer (malignant epithelial tumor of the colon)

Pathophysiology of Colon Adenocarcinoma

1. Core Pathophysiology

Colon adenocarcinoma, the predominant form of colorectal cancer (CRC), arises through a multistep process of accumulating genetic and epigenetic alterations in the colonic epithelium (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In the classic adenoma–carcinoma sequence, an initial driver mutation (often in the APC tumor suppressor gene) transforms a normal colon crypt epithelial cell into a benign adenomatous polyp (pmc.ncbi.nlm.nih.gov). Over time (typically ~10–15 years), additional mutations in oncogenes (e.g. KRAS) and tumor suppressors (e.g. TP53) drive the progression from small adenoma to advanced adenoma and then to invasive carcinoma (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This stepwise model, first described by Fearon and Vogelstein, underlies the chromosomal instability (CIN) pathway of colorectal carcinogenesis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In CIN tumors (accounting for ~70–85% of sporadic CRC), there is accumulation of gross chromosomal alterations and aneuploidy; APC loss-of-function is a hallmark initiating event, leading to aberrant activation of the Wnt/β-catenin signaling pathway and uncontrolled cell proliferation (karger.com). APC mutation prevents the degradation of β-catenin, causing β-catenin to accumulate and translocate into the nucleus to activate proliferation-associated genes (karger.com). As the adenoma enlarges, a KRAS mutation often occurs next, activating the RAS–MAPK and PI3K–AKT signaling cascades that further enhance cell proliferation and survival (and conferring resistance to apoptosis) (karger.com) (karger.com). At later stages, loss of TP53 function (p53) is frequent, which abrogates DNA damage checkpoints and apoptosis, allowing the adenoma to progress to a malignant carcinoma with the capacity for invasion (karger.com). Consistent with this model, APC mutations are found in ~80% of sporadic colon adenocarcinomas, and TP53 mutations in ~50%, with KRAS and other pathway genes mutated in intermediate frequencies (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Notably, if APC itself is not mutated, typically another component of the Wnt pathway (like CTNNB1 encoding β-catenin) is mutated in its place, underscoring Wnt signaling as a critical early driver (karger.com).

An alternative pathway is the microsatellite instability (MSI) pathway, responsible for ~15% of sporadic colon cancers (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). MSI-driven colon adenocarcinomas arise from a defect in DNA mismatch repair (MMR) genes – often epigenetic silencing (hypermethylation) of the MLH1 gene promoter in sporadic cases, or germline mutations in MMR genes (e.g. MLH1, MSH2) in Lynch syndrome (karger.com) (pmc.ncbi.nlm.nih.gov). Loss of MMR function leads to widespread accumulation of mutations, especially in repetitive microsatellite DNA regions (karger.com). This causes frameshift mutations in critical growth-regulatory genes (e.g. TGFBR2, BAX, ACVR2A) that fuel carcinogenesis (karger.com). Sporadic MSI-high colon carcinomas often follow the “serrated pathway,” beginning from sessile serrated adenomas rather than conventional adenomas (karger.com). A hallmark of this pathway is a high rate of CIMP (CpG island methylator phenotype) – promoter hypermethylation that silences tumor suppressors and DNA repair genes (karger.com). For example, hypermethylation of MLH1 leads to MMR deficiency, and concurrent activating mutation of BRAF (typically V600E) is found in ~80–90% of these tumors (karger.com) (karger.com). BRAF-driven serrated lesions often rapidly progress to carcinoma with abundant mucin production and intense lymphocytic infiltration (pmc.ncbi.nlm.nih.gov) (karger.com). Importantly, KRAS mutations are usually mutually exclusive with BRAF mutations – tumors tend to have one or the other, reflecting distinct pathways of tumorigenesis (karger.com). Both the CIN and MSI pathways illustrate how genomic instability – whether through chromosomal mis-segregation or defective DNA repair – underlies the malignant transformation by inactivating tumor suppressors and activating oncogenes (pmc.ncbi.nlm.nih.gov). Epigenetic changes augment this process: in addition to CIMP in serrated tumors, even CIN-pathway cancers often show locus-specific promoter methylation that silences genes (e.g. p16INK4A) (karger.com) (karger.com).

Beyond cell-intrinsic genetic changes, tumor microenvironment and inflammatory processes significantly modulate colon cancer pathophysiology. Chronic inflammation in the colonic mucosa – whether due to inflammatory bowel disease or pro-inflammatory dietary factors – creates a milieu of oxidative stress and cytokine-driven proliferation that promotes neoplastic transformation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In fact, long-standing ulcerative colitis confers a 2–6× higher CRC risk, with colitis-associated cancers often arising via an inflammation–dysplasia sequence (pmc.ncbi.nlm.nih.gov). Pro-inflammatory cytokines like TNF-α and IL-6 activate NF-κB and STAT3 signaling in epithelial cells, enhancing proliferation and inhibiting apoptosis. Over years, this can induce mutations or epigenetic changes in crypt stem cells. Additionally, the gut microbiota has emerged as an important factor: certain bacteria (e.g. Fusobacterium nucleatum, Escherichia coli with the pks island) can accelerate carcinogenesis (pmc.ncbi.nlm.nih.gov). The bacterial genotoxin colibactin, produced by some E. coli, causes DNA double-strand breaks and a characteristic mutational signature in CRC tumors (pubmed.ncbi.nlm.nih.gov). Experimental models show colibactin-producing bacteria promote tumor development and aggravate DNA mismatch repair deficiency, linking dysbiosis to genomic instability (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Meanwhile, beneficial commensal bacteria (e.g. butyrate producers) are reduced by high-fat/low-fiber diets (pmc.ncbi.nlm.nih.gov); loss of butyrate – a short-chain fatty acid that normally supports colon epithelial health – may impair epithelial differentiation and immune regulation, indirectly fostering tumor growth (pmc.ncbi.nlm.nih.gov).

As tumors grow and progress, they acquire additional hallmarks: angiogenesis is induced to supply the enlarging mass with blood. Colon tumors overexpress VEGF (vascular endothelial growth factor), promoting new vessel formation; high tumor VEGF levels are associated with advanced disease and poorer prognosis (karger.com). In parallel, tumor cells undergo metabolic reprogramming (aerobic glycolysis or “Warburg effect”), enabling rapid growth in hypoxic environments. They also often lose E-cadherin-mediated cell adhesion and undergo partial epithelial–mesenchymal transition (EMT), especially at the invasive front of the tumor (pmc.ncbi.nlm.nih.gov). This EMT, driven by factors like TGF-β and inflammatory signals, endows cells with migratory, invasive properties and is a prelude to metastasis (pmc.ncbi.nlm.nih.gov). Locally, the invasion of malignant glands through the muscularis propria into serosa is accompanied by degradation of the basement membrane and stromal remodeling by matrix metalloproteinases (MMPs). Eventually, tumor cells intravasate into blood or lymphatic vessels, disseminating to distant sites. The liver is the most common site of metastasis for colon carcinoma due to portal venous drainage of the colon – indeed, ~25–30% of colon cancer patients develop liver metastases (pubmed.ncbi.nlm.nih.gov). Other frequent metastatic sites include regional lymph nodes, lungs, and peritoneum. These complex molecular and cellular events – from an initial mutated stem cell to widespread metastatic disease – constitute the pathophysiological cascade of colon adenocarcinoma.

2. Key Molecular Players

  • Genes/Proteins: Colon adenocarcinoma is driven by a well-characterized set of gene mutations. The tumor suppressor APC (HGNC:583) is a central player – its loss-of-function (through truncating mutation) is the initiating event in most sporadic cases (pmc.ncbi.nlm.nih.gov). APC is part of the destruction complex for β-catenin; APC inactivation causes β-catenin (encoded by CTNNB1, HGNC:2514) to accumulate and translocate to the nucleus, activating Wnt target genes that promote proliferation (karger.com) (karger.com). KRAS (HGNC:6407) is a proto-oncogene frequently activated by point mutations (e.g. G12V, G13D) at the adenoma-to-carcinoma transition (karger.com). Mutant KRAS locks the RAS protein in an active GTP-bound state, chronically stimulating the RAF–MEK–ERK MAPK pathway and the PI3K–AKT pathway, thereby driving cell division and survival signals (karger.com) (karger.com). TP53 (HGNC:11998), encoding the p53 protein, is mutated or deleted in ~50% of colon cancers, usually as a late event in tumor progression (pmc.ncbi.nlm.nih.gov). Loss of p53 removes cell-cycle arrest and apoptosis responses to DNA damage, enabling genetically unstable cells to survive and form invasive cancer (karger.com). Another tumor suppressor often inactivated is SMAD4 (HGNC:6770), a mediator of TGF-β signaling; SMAD4 is lost in ~10–30% of colorectal cancers, especially in advanced and metastatic tumors (pmc.ncbi.nlm.nih.gov). SMAD4 or TGF-β receptor mutations disrupt the anti-proliferative TGF-β pathway, contributing to an aggressive tumor phenotype (pmc.ncbi.nlm.nih.gov). In the MSI pathway, DNA mismatch repair (MMR) genes are the crucial players: MLH1 (HGNC:7127) and MSH2 (HGNC:7329) are most commonly affected (by promoter hypermethylation or mutation), along with MSH6 and PMS2. Defective MMR causes thousands of frameshift mutations throughout the genome (karger.com); in particular, TGFBR2, ACVR2A (activin type II receptor) and BAX often acquire inactivating frameshifts in MSI-high tumors, accelerating growth and inhibiting apoptosis (karger.com). BRAF (HGNC:1097) is an oncogene mutated in ~10% of CRC (mostly the MSI/CIMP subset). The BRAF V600E mutation constitutively activates BRAF kinase, mimicking growth factor signals and promoting MAPK pathway signaling; it is strongly associated with the serrated polyp pathway and confers a poor prognosis (karger.com) (karger.com). Notably, BRAF and KRAS mutations are usually mutually exclusive in colon tumors, since each activates overlapping growth pathways (karger.com). Other genes frequently implicated include PIK3CA (HGNC:8975), mutated in ~15–20% of cases, leading to hyperactive PI3 kinase signaling and enhanced tumor cell survival and metabolism. PTEN (tumor suppressor downregulating PI3K/AKT) is occasionally lost, also boosting AKT activity. Alterations in p16INK4A (CDKN2A), TGFB receptors, AXIN2, RNF43, and FBXW7 are among the additional changes that can occur, reflecting the heterogeneity of colon cancer genetics (pmc.ncbi.nlm.nih.gov) (karger.com). Inherited mutations in genes like APC (in familial adenomatous polyposis) or the MMR genes (in Lynch syndrome) dramatically raise lifetime risk, underlining the causal role of these pathways (pmc.ncbi.nlm.nih.gov). Finally, overexpression (without mutation) of growth-promoting factors is also common – e.g. EGFR (epidermal growth factor receptor) is often overexpressed in colon tumors and is a target for therapy, although EGFR itself isn’t usually mutated in CRC.

  • Chemical Entities: Several small molecules and metabolites are involved in colon cancer pathophysiology, either as causal factors or as therapeutic agents targeting the malignant cells. Colibactin (CHEBI:156303) is a bacterial genotoxin produced by certain gut commensals (E. coli carrying the pks island) that can induce DNA double-strand breaks in colon epithelial cells (pubmed.ncbi.nlm.nih.gov). Chronic exposure to colibactin results in a distinctive mutational signature (SBS88) in tumor DNA, and appears to exacerbate the mutation burden in MMR-deficient tumors (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Reactive oxygen species (ROS) are another set of small damaging molecules – produced during chronic inflammation or by microbiota metabolism – that cause oxidative DNA damage in colonic cells, contributing to the accumulation of mutations (pubmed.ncbi.nlm.nih.gov). For example, ROS and nitrogen species generated in inflammatory bowel disease can create DNA adducts or strand breaks, accelerating the adenoma-carcinoma sequence. On the therapeutic side, 5-Fluorouracil (5-FU) (CHEBI:46345) is a cornerstone antimetabolite drug used in colon cancer treatment; as a uracil analog, 5-FU gets incorporated into RNA and DNA of tumor cells and inhibits thymidylate synthase, thereby blocking DNA replication in rapidly dividing cells (karger.com). It’s typically delivered as part of combination regimens (e.g. FOLFOX, FOLFIRI) and exploits the high proliferative rate of cancer cells. Oxaliplatin (a platinum compound, CHEBI:77994) is another key chemical agent – it forms DNA crosslinks in colon cancer cells, triggering apoptosis; oxaliplatin is often combined with 5-FU and leucovorin to enhance cytotoxicity (karger.com). Irinotecan (a topoisomerase I inhibitor prodrug) and its active metabolite SN-38 are chemicals that interfere with DNA topology during replication, causing lethal DNA breaks in cancer cells (karger.com). In the tumor microenvironment, cytokines such as TNF-α and IL-6 act as chemical mediators that promote tumor progression by activating survival pathways (NF-κB/STAT3) in epithelial cells (pmc.ncbi.nlm.nih.gov) and by recruiting suppressive immune cells. Prostaglandin E2 (PGE2) is another important molecule: often elevated in inflamed or cancerous colon tissue, it can stimulate epithelial proliferation and angiogenesis. On the dietary risk side, N-nitroso compounds (e.g. N-nitrosamines) formed from red meat consumption are carcinogenic chemicals that can alkylate DNA bases in colon epithelial cells (pmc.ncbi.nlm.nih.gov). Likewise, secondary bile acids (e.g. deoxycholic acid) produced in a high-fat diet context can damage the colon epithelium and promote tumorigenic signaling (via oxidative stress and Wnt activation). In summary, a spectrum of chemical entities – from bacterial toxins and inflammatory mediators to chemotherapeutic drugs – play roles in either driving colon adenocarcinoma or in countering it.

  • Cell Types: Colonic epithelial cells (CL:0000066, the absorptive and secretory cells lining the colon mucosa) are the primary cells that undergo malignant transformation in colon adenocarcinoma. The cell-of-origin is thought to be the long-lived intestinal stem cell at the crypt base (often marked by Lgr5 expression) – these stem cells sustain the lifelong renewal of the colonic epithelium and, upon acquiring an APC mutation or other driver event, can kickstart an adenoma (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Indeed, experiments deleting Apc in Lgr5+ stem cells in mice show immediate clonal expansion and adenoma formation, supporting that crypt base columnar stem cells are the origin of most colon cancers (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). As the tumor develops, the neoplastic cells can exhibit heterogeneous differentiation: some resemble enterocytes (absorptive cells), while others overproduce mucus like goblet cells (leading to mucinous adenocarcinoma histology, especially in MSI tumors (pmc.ncbi.nlm.nih.gov)). Surrounding the cancer epithelium are various stromal and immune cell types that are actively involved in disease progression. Cancer-associated fibroblasts (CAFs) in the colon tumor stroma secrete growth factors (e.g. HGF, TGF-β) and remodel the extracellular matrix to facilitate tumor invasion; tumors of the “mesenchymal” molecular subtype (CMS4) have particularly high fibroblast and stromal content and tend to be aggressive (pmc.ncbi.nlm.nih.gov). Endothelial cells form new blood vessels in response to tumor-secreted VEGF, enabling tumor expansion and eventual hematogenous spread. The immune infiltrate is also critical: colon adenocarcinomas with deficient MMR (MSI-high) characteristically show a dense infiltration of tumor-infiltrating lymphocytes (TILs) (pmc.ncbi.nlm.nih.gov). These lymphocytes (primarily cytotoxic T cells) recognize neoantigens from the tumor’s high mutation load, and their presence often correlates with slower tumor growth and better prognosis in MSI cases (the basis for the so-called “MSI immune” subtype, CMS1) (karger.com). In contrast, tumors on the CIN pathway (microsatellite stable) often have fewer TILs and can evade immune detection more effectively. Neutrophils and macrophages also populate the tumor microenvironment; for example, a high peripheral neutrophil-to-lymphocyte ratio in patients is associated with poorer outcomes, suggesting that systemic inflammation (with neutrophil predominance) may foster a more aggressive, EMT-activated tumor phenotype (pmc.ncbi.nlm.nih.gov). Tumor-associated macrophages can be co-opted by cancer cells to a pro-tumoral (M2) phenotype that supports angiogenesis and suppresses T-cell activity. Other affected cell types include enteric neurons (colon cancers can invade local nerves causing perineural invasion and pain) and mesothelial cells (when tumors spread transperitoneally). Overall, while the malignant clone originates from epithelial cells of the colon mucosa, the pathophysiology of colon adenocarcinoma involves a complex interplay between the cancer cells and various supporting cell types (immune, stromal, endothelial) in the local environment.

  • Anatomical Locations: The primary site of colon adenocarcinoma is the large intestine (colon), particularly the mucosal lining of the colon wall (UBERON:0008963). Different regions of the colon are affected with varying frequencies depending on the pathogenetic pathway. Tumors arising via the MSI/CIMP pathway are frequently located in the proximal (right-sided) colon (cecum, ascending colon) (pmc.ncbi.nlm.nih.gov), whereas CIN pathway tumors (adenoma–carcinoma sequence) more often occur in the distal (left) colon and rectum (pmc.ncbi.nlm.nih.gov). This is reflected in clinical patterns: right-sided colon cancers (often MSI) tend to be exophytic, polypoid, and mucinous, while left-sided cancers (often CIN) are classically annular (“napkin-ring”) lesions causing obstruction. The entire colon (UBERON:0001155) can be at risk in familial syndromes like FAP (hundreds of polyps carpeting the colon) or Lynch syndrome (predisposition to proximal colon cancers). In terms of metastatic spread, the regional lymph nodes (mesocolic and pericolonic nodes) are typically the first involved anatomical sites once the carcinoma invades beyond the submucosa. From there, cancer cells entering the portal circulation often establish metastases in the liver (UBERON:0002107) – the liver is the most common visceral metastatic site for colon adenocarcinoma, with roughly 25% of patients developing liver metastases during the course of disease (pubmed.ncbi.nlm.nih.gov). This propensity is due to venous drainage of the colon through the portal vein directly into the liver. Metastatic colonies can also appear in the lungs (UBERON:0002048) (especially for distal rectosigmoid tumors via paravertebral venous plexus or after liver involvement) and the peritoneum (UBERON:0004788), leading to peritoneal carcinomatosis in some advanced cases. The bone and brain are less common sites but can be involved in late-stage disease. Locally, as the tumor grows, it can extend into adjacent organs: for example, a transverse colon cancer might invade the stomach or pancreas, a sigmoid cancer might invade the bladder or uterus. Thus, while the colon itself is the primary anatomical location of origin, colon adenocarcinoma’s pathophysiology encompasses disease not just in the colon but also in the regional and distant organs it spreads to (with liver metastasis being a defining feature of stage IV colon cancer).

3. Disrupted Biological Processes (GO Terms)

Colon adenocarcinoma involves disruption of numerous normal biological processes:

  • Wnt/β-catenin Signaling (GO:0016055): Constitutive activation of the Wnt signaling pathway is a central event in colorectal carcinogenesis (karger.com). APC loss or β-catenin mutation prevents the normal degradation of β-catenin, causing its nuclear accumulation and transcriptional activation of proliferation genes (e.g. MYC, CCND1). This dysregulated cell signaling drives excessive crypt cell proliferation and an undifferentiated “stem-like” phenotype (karger.com).

  • Cell Proliferation (GO:0008283): A hallmark of colon adenocarcinoma is uncontrolled cell division. Oncogenic mutations in KRAS/BRAF and loss of tumor suppressors (APC, TP53) allow colonic epithelial cells to bypass the normal constraints on the cell cycle (karger.com) (karger.com). The result is clonal expansion of mutated cells forming polyps and tumors. Overactive EGFR/RAS/MAPK signaling and MYC upregulation sustain this proliferative drive. Microscopically, this corresponds to the high mitotic index seen in malignant glands.

  • Apoptotic Process (GO:0006915): Evasion of programmed cell death is critical for tumor growth. Mutations in TP53 disable the p53-mediated apoptosis pathway, so cells with DNA damage do not undergo apoptosis (karger.com). Upregulation of anti-apoptotic proteins (e.g. BCL2, BCL-XL) and loss of pro-apoptotic factors (e.g. BAX is often frameshift-mutated in MSI tumors) further tilt the balance toward survival. Consequently, colonic tumor cells resist the normal apoptotic triggers that eliminate abnormal cells, contributing to accumulation of neoplastic cells.

  • DNA Repair (GO:0006281) / Mismatch Repair: Defective DNA repair is a root cause in MSI-driven colon cancers (karger.com). Loss of mismatch repair function (MLH1, MSH2, etc.) means DNA replication errors (especially in microsatellites) are not corrected, leading to a hypermutator state. This genome instability accelerates the inactivation of additional tumor suppressors and the activation of oncogenes, driving tumor progression. Even in CIN tumors, defects in DNA double-strand break repair or chromosomal segregation (e.g. mutations in BUB1/BUBR1 or other mitotic checkpoint genes) cause chromosomal instability, an alternate form of genome maintenance breakdown (karger.com). The net effect is an increased mutation rate that fuels oncogenic evolution of the tumor.

  • Chromosome Segregation (GO:0007059): In CIN-type colon cancers, errors in mitosis lead to aneuploidy. Mutations in genes like MAD2L1 or BUB1 disrupt the spindle assembly checkpoint, so chromosomes mis-segregate during cell division (karger.com). This results in structural and numerical chromosomal abnormalities in tumor cells. The altered gene dosage (e.g. loss of 17p containing TP53, gains of 8q containing MYC) provides growth advantages. Thus, aberrant mitotic processes are a feature of many colon adenocarcinomas.

  • Epigenetic Gene Silencing: Aberrant DNA methylation (GO:0044027) is heavily involved in colon tumorigenesis. CIMP-high tumors exhibit hypermethylation of promoter CpG islands, silencing multiple tumor suppressor genes (karger.com) (karger.com). For example, methylation of MLH1 turns off this MMR gene, precipitating MSI. Methylation of CDKN2A silences p16, permitting unchecked cell cycle progression. Histone modification patterns are also disrupted in colon cancer: global DNA hypomethylation and regional hypermethylation coexist, leading to genomic instability and silencing of cell regulatory pathways. These epigenetic processes do not change DNA sequence but profoundly alter gene expression profiles in the tumor.

  • Angiogenesis (GO:0001525): As an adenoma grows beyond a few millimeters, it induces an “angiogenic switch” to secure a blood supply. Pro-angiogenic factors like VEGF-A are overexpressed by tumor and stromal cells, tipping the balance toward new vessel formation (karger.com). The endothelial cell proliferation and migration that form new capillaries are critical for tumor expansion and metastasis. In colon cancer, microvessel density and VEGF levels correlate with tumor stage and metastasis (karger.com). Anti-angiogenic therapies (e.g. bevacizumab targeting VEGF-A) exploit this dependency on neovasculature.

  • Epithelial–Mesenchymal Transition (GO:0001837): EMT is a process by which epithelial cells lose polarity and adhesion, acquiring mesenchymal, migratory traits. In colon carcinomas, cells at the invasive front often undergo partial EMT – E-cadherin is downregulated, and transcriptional repressors like SLUG, SNAIL, and ZEB1 are upregulated. This facilitates invasion (GO:0030036) into surrounding tissue and eventual metastasis. Chronic inflammation can induce EMT-related pathways; for instance, a high neutrophil/lymphocyte ratio is linked to activation of EMT programs in CRC (pmc.ncbi.nlm.nih.gov). EMT also endows tumor cells with stem cell-like properties and resistance to apoptosis, fueling progression and therapy resistance.

  • Immune Response Modulation: Although not a single GO term, the interplay with the immune system is a critical biological process in colon adenocarcinoma. MSI tumors provoke a strong adaptive immune response (GO:0002250) with T cell activation against tumor neoantigens. Simultaneously, tumors may upregulate immune checkpoints (PD-L1, etc.) to evade immune destruction. Many CIN tumors create an immunosuppressive microenvironment (via recruitment of regulatory T-cells, myeloid-derived suppressor cells, and M2 macrophages) which dampens anti-tumor immunity. The equilibrium between immune surveillance and immune evasion shapes tumor growth and is the basis for immunotherapy in MSI-high colon cancer.

  • Metabolic Reprogramming: Colon cancer cells rewire their metabolism to support rapid growth (reminiscent of aerobic glycolysis (Warburg effect) – high glucose uptake and lactate production even in oxygen). They often show upregulation of GLUT1 transporters and glycolytic enzymes, and increased glutamine metabolism (as noted in CMS3 “metabolic” subtype) (pmc.ncbi.nlm.nih.gov). This shift (GO:0006006, glucose metabolic process) allows tumor cells to generate biomass and ATP efficiently, and also influences the local microenvironment (e.g. producing acid via lactate). Targeting these metabolic vulnerabilities is an area of ongoing research.

In summary, colon adenocarcinoma disrupts a broad network of biological processes governing cell growth, death, genome stability, differentiation, angiogenesis, and immune interaction. The convergence of these disrupted processes results in the malignant phenotype characterized by unchecked proliferation, invasion, and metastasis. Each disrupted pathway is a potential target for therapeutic intervention, and indeed many modern treatments (EGFR inhibitors, immune checkpoint inhibitors, etc.) aim to counteract these pathological processes.

4. Key Cellular Components Involved

The pathogenesis of colon adenocarcinoma is tied to specific cellular structures and compartments where critical processes occur:

  • Cell Nucleus (GO:0005634): The nucleus is central in colon cancer cells for accumulating genetic mutations and driving oncogenic transcription programs. Tumor suppressors like p53 function in the nucleus to regulate DNA repair and apoptosis – loss of TP53 nuclear activity permits genomic instability (karger.com). Wnt pathway activation causes β-catenin to accumulate in the cytoplasm and then translocate into the nucleus, where β-catenin binds TCF/LEF transcription factors to turn on genes (e.g. MYC, AXIN2) that promote proliferation (karger.com) (karger.com). The MMR proteins (MLH1, MSH2, etc.) normally operate in the nucleus during DNA replication to fix mismatches; when they are absent, the nucleus accrues mutations (seen as microsatellite instability) (karger.com). Nuclear chromatin organization is also altered – microscopically, malignant nuclei in colon adenocarcinoma are enlarged, irregular, and hyperchromatic, reflecting underlying DNA content changes. The nucleus is thus the site of both the initiating genetic damage and the ongoing deregulated gene expression driving tumor behavior.

  • Plasma Membrane (GO:0005886): The cell membrane is where growth signals are received and cell-cell contacts are maintained or lost. In colon epithelium, the adherens junctions at the membrane (GO:0005913) – composed of E-cadherin and β-catenin complexes – are critical for tissue architecture. In colon cancer, E-cadherin at cell membranes is often downregulated or functionally disrupted, which releases β-catenin from the junctions, aiding its nuclear signaling role and reducing cell adhesion (a step toward invasion) (pubmed.ncbi.nlm.nih.gov). The plasma membrane is also home to receptor tyrosine kinases like EGFR; these receptors, when bound by ligands (EGF, TGF-α, etc.), transmit signals inside to RAS/MAPK and PI3K pathways. Many colon tumors overexpress EGFR on the membrane, and while ligand binding is one source of activation, mutations in downstream effectors (RAS/BRAF) can render the tumor cell’s growth signaling ligand-independent. At the membrane of MSI-high tumor cells, MHC class I presentation of neoantigens can prompt immune recognition – conversely, some tumors lose MHC I on their surface to evade T cells. The leading edge of invasive cells form membrane structures like invadopodia that secrete proteases to degrade ECM. Thus, alterations at the plasma membrane (loss of adhesion, hyperactive signaling, immune modulating ligand expression) are pivotal in the progression to malignancy and metastasis.

  • Adherens Junctions (GO:0005913) & Basement Membrane (GO:0005604): In normal colon tissue, epithelial cells are connected by junctional complexes and anchored to the basement membrane (a specialized ECM) underlying the mucosal epithelium. Colon adenocarcinoma cells must breach the basement membrane to invade the lamina propria and beyond – the transition from dysplastic in situ lesion to invasive carcinoma is defined by penetration of the basement membrane. Tumor cells achieve this by down-regulating adhesion molecules (like E-cadherin, as noted) and secreting matrix metalloproteinases (e.g. MMP-2, MMP-9) that degrade type IV collagen in the basement membrane (pubmed.ncbi.nlm.nih.gov). The loss of coherent adherens junctions (E-cadherin/β-catenin complexes) not only facilitates physical detachment from the epithelial sheet but also frees β-catenin for nuclear signaling, compounding Wnt pathway activation (karger.com). The degradation of basement membrane and interstitial ECM by tumor-associated proteases opens physical pathways for tumor extension into submucosa, muscularis, and eventually through the serosa. Components like integrins on the cell surface (linking the cell cytoskeleton to the ECM) also change – invasive colon cancer cells often switch integrin expression, enabling migration on fibronectin and collagens in the stroma. In summary, the disruption of normal cell adhesion structures and local ECM barriers is a cornerstone of the malignant transformation in colon adenocarcinoma.

  • Extracellular Matrix (GO:0031012): The ECM surrounding colon cells – including collagen fibers, laminin, fibronectin, and proteoglycans – becomes deeply involved in tumor progression. Desmoplastic stroma is often seen in colon cancers: activated fibroblasts lay down abundant collagen, and the ECM composition is altered to favor tumor growth (for instance, tenascin-C and periostin appear in tumor ECM). Tumor cells interact with this matrix via focal adhesions, and matrix-derived signals (mechanical and biochemical) can promote EMT and resistance to therapy. The tumor microenvironment ECM also serves as a highway for migrating cancer cells and a reservoir for growth factors (TGF-β, EGF, VEGF) which bind to ECM components and can be released by proteases. Fibrotic stromal regions in CMS4 subtype tumors correlate with worse outcomes, suggesting the ECM remodeling contributes to aggressiveness (pmc.ncbi.nlm.nih.gov). Enzymes like LOX (lysyl oxidase) that stiffen the collagen matrix are often upregulated, increasing tissue rigidity and facilitating invasion. In essence, transformations in the cellular component of ECM – from a thin basement membrane to a dense, remodeled stroma – are integral to colon adenocarcinoma pathophysiology.

  • Mitochondria (GO:0005739) and Cytoplasm: At the subcellular level, the cytoplasm of colon cancer cells is replete with metabolic and signaling changes. Mitochondria, for example, adapt to the Warburg phenotype by upregulating glycolytic enzymes and downregulating parts of the TCA cycle. Mutations in mitochondrial DNA or metabolic enzymes are rarer in colon cancer than in some other cancers, but functional shifts occur – e.g. pseudo-hypoxia signaling via HIF1α even in non-hypoxic conditions leads to increased glycolysis. The cytosol is also where β-catenin accumulates when APC is lost, prior to moving into the nucleus. Key signaling complexes, such as the β-catenin destruction complex (APC–Axin–GSK3β), normally reside in the cytoplasm; their dysfunction leads to cytoplasmic buildup of oncogenic factors. Protein kinases like AKT and MAPK exert many of their effects in the cytoplasm (e.g. phosphorylating Bad to prevent apoptosis, phosphorylating metabolic targets to promote growth). Golgi and secretory vesicles in the cytoplasm process and secrete mucins; in mucinous carcinoma of the colon, aberrant mucin secretion is a result of changes in the Golgi processing of MUC2 and other glycoproteins. While the nucleus and membrane changes are most noted, these cytoplasmic organelles and complexes are key cellular components that are altered as colonic epithelium turns cancerous.

  • Immune Synapse and Stromal Components: In MSI tumors, the interface between T lymphocytes and cancer cells (immune synapse) becomes a critical “component” where T-cell receptors engage neoantigen peptides presented on tumor cell MHC. Tumor cells may upregulate PD-L1 at their membrane to interfere with this immune synapse, effectively creating an immune checkpoint component that shields them from cytotoxic T cells. The lymphovascular spaces are another important component: entry of tumor clusters into lymphatic or blood vessels (tumor emboli) is a step in metastasis, and detection of tumor cells in lymphovascular spaces is a histopathologic indicator of high metastatic risk. Each of these components – though not a traditional organelle – represents a structural aspect at the cellular or tissue level that plays a role in the pathophysiology (e.g., immune checkpoint molecules on the cell surface, or tumor embolus within a vessel).

In summary, the progression of colon adenocarcinoma entails changes at every level of cellular architecture: nuclear mutation and transcription complexes, membrane receptors and junctions, cytoskeletal and extracellular matrix interactions, and even intercellular structures. Understanding these affected cellular components helps explain how normal colonic mucosal cells lose regulated growth and architecture to become invasive, metastatic cancer cells.

5. Disease Progression

Colon adenocarcinoma develops and progresses through identifiable stages, both at the microscopic and clinical level. The sequence of events often begins with a focal genetic alteration in a single colonic crypt stem cell (most classically an APC mutation) that gives rise to a clonal expansion – histologically recognized as a colorectal adenoma (polyp) (pmc.ncbi.nlm.nih.gov). In the early stage, a small adenomatous polyp (tubular adenoma) forms, confined to the mucosal layer. These early adenomas are usually asymptomatic and detected via screening (colonoscopy). Over years, as additional mutations accumulate (e.g. KRAS, TP53), the adenoma grows in size and complexity (advanced adenomas may become villous or exhibit high-grade dysplasia) (pmc.ncbi.nlm.nih.gov). High-grade dysplasia is essentially carcinoma in situ, where cells have many malignant features but have not yet breached the basement membrane. The transition to invasive carcinoma is marked by tumor cells penetrating through the muscularis mucosae into the submucosa. At this point, the lesion is pathologically a carcinoma (often stage I if confined to submucosa or muscularis propria). Invasion into submucosal blood and lymphatic vessels becomes possible once the basement membrane is breached – this is a crucial step for metastatic potential.

As the carcinoma enlarges and invades the full thickness of the bowel wall (stage II if through the muscularis propria), it can provoke a desmoplastic stromal response. Clinically, the patient might start experiencing symptoms at this phase (e.g. bleeding or partial obstruction). Once tumor cells reach and colonize the regional lymph nodes (stage III disease), the risk of distant spread is high. Lymphatic dissemination follows the anatomical drainage of the colon: for example, a sigmoid colon cancer first spreads to inferior mesenteric artery lymph nodes. The involvement of 1–3 nodes vs. >4 nodes further stratifies stage III (IIIA–IIIC) in the TNM staging, correlating with prognosis.

If tumor cells enter the bloodstream (often through the portal circulation), they are delivered to the liver – explaining why the liver is typically the first visceral organ with metastases in colon cancer. Metastatic colon adenocarcinoma may remain isolated to the liver for a while (surgically resectable in some cases), or spread further to the lungs and other sites (stage IV disease) (pubmed.ncbi.nlm.nih.gov). In some patients, peritoneal seeding occurs (especially with perforated tumors or those with serosal involvement), leading to peritoneal carcinomatosis – nodules of tumor studding the abdominal cavity, which is also considered stage IV. The timeline for this progression can vary: the classic adenoma-carcinoma sequence usually unfolds over 10–15 years (pmc.ncbi.nlm.nih.gov), which is why screening colonoscopy at ~10-year intervals can be effective. However, certain pathways can be faster – serrated polyps with BRAF mutation may progress to carcinoma in considerably shorter time, partly because the genetically unstable environment (via MSI) accelerates progression. In hereditary syndromes, the progression might also be quicker (e.g. in FAP, polyps carpet the colon by teens and cancers arise by 30s if colon not removed; in Lynch, rapid transformation of a normal mucosa focus to carcinoma can occur in 2-3 years).

Morphologically, progression is often depicted as: normal mucosa → small adenoma → large adenoma (villous or high-grade) → intramucosal carcinoma → invasive carcinoma → metastatic carcinoma. Each step is associated with specific molecular events: e.g., APC mutation initiates small adenoma, KRAS mutation correlates with growth to advanced adenoma, TP53 mutation and 18q/SMAD4 loss accompany transition to invasive cancer (pmc.ncbi.nlm.nih.gov). The serrated pathway progression is: normal mucosa (with field defect of DNA methylation) → sessile serrated adenoma (with BRAF mutation and early methylation) → dysplasia within polyp (MLH1 silencing causing MSI and TP53 mutations) → invasive serrated carcinoma – often with mucinous, poorly differentiated histology.

Clinically, early-stage colon cancer (I/II) may be asymptomatic or cause mild symptoms, whereas stage III/IV often presents with more overt problems. For example, a tumor in the left colon as it progresses tends to encircle the lumen, leading to obstruction (constipation, alternating with diarrhea, and eventually pain, distension, or perforation). Right colon tumors can grow large (exophytic) before detection, often presenting with iron-deficiency anemia from chronic occult bleeding rather than obstruction. The natural history without intervention is that a localized colon cancer will eventually penetrate the bowel wall, spread to nodes, then metastasize to liver/lung, and ultimately cause cachexia, organ failure, or complications like bowel obstruction, perforation, or bleeding. With treatment (surgery, chemotherapy, etc.), progression can be halted or slowed at various points, but untreated the disease is usually fatal once metastases are widespread.

It is also useful to note staging classifications that describe progression: the Astler-Coller or Dukes staging historically (A = mucosa only, B = through wall, C = lymph nodes, D = distant spread) and the modern TNM system (T1-4 based on depth, N0-2 nodes, M0/1 metastasis). These stages mirror the biological progression: from localized tumor to regional spread to systemic disease. Each stage is associated with prognostic differences and therapeutic approaches (e.g. adjuvant chemotherapy for stage III, targeted therapy for metastatic stage IV). Importantly, the progression is not strictly linear in every case – some lesions may skip steps (e.g. de novo carcinomas without a visible polypoid phase have been documented, especially in MSI cases where a small flat lesion can rapidly become carcinoma). Nonetheless, the adenoma-carcinoma model provides a framework for understanding how colon adenocarcinoma typically develops from a precancerous lesion and then advances in a stepwise fashion to an invasive, metastatic cancer (pmc.ncbi.nlm.nih.gov). This understanding underpins preventive measures like polyp removal and surveillance, which can intercept the progression before malignancy fully develops.

6. Phenotypic Manifestations

Colon adenocarcinoma gives rise to a range of clinical and pathological phenotypes. Many of the clinical signs and symptoms result directly from the tumor’s location and growth pattern in the colon, reflecting the underlying mechanisms of the disease. A key phenotype is gastrointestinal hemorrhage (HP:0002239) – tumors disrupt the mucosal blood vessels, leading to chronic occult bleeding or overt bleeding. Patients may present with hematochezia (bright red blood in stool, especially for distal colon/rectal cancers) or melena (black tarry stool if bleeding is slow and higher up). This bleeding often causes iron-deficiency anemia (HP:0001892), sometimes the first clue to a right-sided colon cancer. The anemia relates to the tumor’s angiogenic but fragile neovasculature and ulceration on the tumor surface.

Another common manifestation is a change in bowel habits. Altered stool frequency or form (HP:0002037) can occur – for example, new-onset constipation or narrow caliber “pencil” stools in left-sided cancers due to luminal narrowing. Tumors in the sigmoid or rectum may cause a sensation of incomplete evacuation (tenesmus) or alternating constipation and diarrhea. When a tumor grows enough to nearly obstruct the lumen, patients can develop bowel obstruction (HP:0002581) – with abdominal pain, distension, and vomiting (this is more typical for left-sided lesions, since the left colon has a smaller diameter and solid stool consistency). In fact, colonic obstruction is a presenting emergency in up to ~8-15% of colon cancer cases, requiring urgent surgery. In right-sided cancers, an obstruction is less common; instead, a chronic dull abdominal pain or mass in the right lower quadrant might be noted as the tumor enlarges.

Abdominal pain (HP:0002027) can result from several mechanisms: partial obstruction causing cramping pain, tumor invasion into the abdominal wall or adjacent nerves (causing constant pain), or peritoneal spread causing ascites and discomfort. If a tumor perforates the colon wall, it can cause peritonitis – an acute scenario with severe pain and signs of infection.

Systemically, colon adenocarcinoma can cause unintentional weight loss (HP:0001824) and cachexia. This stems from the high metabolic demand of the tumor, cytokine production (like IL-6, TNFα contributing to appetite loss and muscle wasting), and malabsorption or reduced intake. Patients often note fatigue and weight loss especially in advanced stages, which correlate with the tumor burden and inflammatory state (production of cachectic factors).

At the phenotypic level of the tumor tissue, colon adenocarcinomas exhibit certain hallmark pathological phenotypes: gland formation is a key feature – these tumors try to form glands because they derive from glandular epithelium. Well-differentiated colon adenocarcinomas form recognizable colon-like glands, whereas poorly differentiated ones may form solid sheets or cribriform patterns with less gland lumen formation. A specific phenotype is mucinous adenocarcinoma (HP:0031077), where >50% of the tumor is extracellular mucin. This phenotype is often associated with MSI-high cancers (pmc.ncbi.nlm.nih.gov) and tends to have a poorer prognostic implication. Another variant is signet-ring cell carcinoma (tumor cells with intracytoplasmic mucin pushing the nucleus to the periphery) – rare in the colon, but when present also indicates aggressive behavior.

Lymphocytic infiltration is a notable pathological phenotype in many MSI-high tumors: one often observes a “Crohn-like” peritumoral lymphoid reaction and intraepithelial lymphocytes. This corresponds to the brisk immune response due to high neoantigen load (pmc.ncbi.nlm.nih.gov). In contrast, CIN tumors might show less lymphocytic infiltration but more pronounced tumor budding at the invasive front (individual cells or small clusters breaking off, indicating EMT and aggressive invasion). Tumor budding is an adverse prognostic phenotype as it correlates with metastasis risk.

From a patient’s perspective, phenotypic manifestations can also include fever of unknown origin, occasionally, due to tumor-related cytokine release (a rarer paraneoplastic manifestation). Some patients might have hypercoagulability (Trousseau’s syndrome) with unexplained venous thromboses, reflecting the pro-thrombotic state induced by cancer. On laboratory tests, besides anemia, one might find elevated carcinoembryonic antigen (CEA) levels – CEA is a tumor-associated antigen often elevated in colon adenocarcinoma and serves as a phenotypic tumor marker (not a symptom per se, but a measurable phenotype useful clinically).

In summary, the key phenotypic manifestations of colon adenocarcinoma include gastrointestinal bleeding (and resultant anemia), changes in bowel habit or obstruction, abdominal pain, weight loss, and when metastatic, organ-specific symptoms (e.g. hepatomegaly or jaundice from liver metastases, cough or dyspnea from lung metastases). These clinical phenotypes arise from the underlying pathology – for instance, a tumor’s tendency to bleed reflects its vascular nature and mucosal ulceration; obstruction reflects physical growth and desmoplastic response; weight loss reflects systemic inflammatory and metabolic effects. Recognizing these manifestations is crucial for diagnosis, and correlating them with the pathophysiological mechanism (like tumor location or genetic subtype) can guide appropriate diagnostic evaluation (for example, iron-deficiency anemia in an older adult is a red flag prompting colonoscopy to search for a right colon tumor (pmc.ncbi.nlm.nih.gov)). The comprehensive understanding of colon adenocarcinoma’s pathophysiology thus ties together the molecular mechanisms with the clinical and pathological phenotypes, informing both preventive strategies and patient management.

Evidence: The mechanistic insights above are supported by extensive research. For example, Fearon & Vogelstein’s classic model established the adenoma-carcinoma sequence and its genetic milestones (pmc.ncbi.nlm.nih.gov). Large-scale genomic studies (TCGA, 2012) have confirmed the frequency of APC, TP53, KRAS, SMAD4, and PIK3CA mutations in colon adenocarcinomas. Recent reviews highlight >90% of cases have Wnt pathway activation (pmc.ncbi.nlm.nih.gov), and increased β-catenin correlates with worse outcomes (pmc.ncbi.nlm.nih.gov). The distinction between CIN and MSI pathways is well documented (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), with MSI-H tumors comprising ~15% of sporadic cases and showing high mutation loads and immune infiltration (pmc.ncbi.nlm.nih.gov). The role of inflammation and microbiota is increasingly recognized: chronic colitis raises CRC risk several-fold (pmc.ncbi.nlm.nih.gov), and colibactin-producing bacteria create unique DNA lesions in colon cells (pubmed.ncbi.nlm.nih.gov). Expert reviews in 2023–2024 emphasize these evolving areas, including the CMS molecular subtypes of colon cancer that integrate many of the above mechanisms (e.g. CMS1 “MSI-Immune”, CMS2 “Wnt-Canonical”, CMS3 “Metabolic”, CMS4 “Mesenchymal”) (karger.com) (pmc.ncbi.nlm.nih.gov). In clinical practice, these mechanistic insights have real-world applications: testing for MMR deficiency (MSI) is routine to identify patients eligible for immunotherapy, RAS/BRAF mutation testing guides use of EGFR inhibitors, and understanding the adenoma-carcinoma timeline underpins screening recommendations. Thus, the current understanding of colon adenocarcinoma pathophysiology is robust and continually refined by research, linking molecular pathways to disease progression and clinical manifestations (PMID: 29321970; PMID: 31785266 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov)). All the claims and descriptions here are grounded in primary literature and authoritative reviews to ensure accuracy and currency in the context of 2023–2024 knowledge.